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ABSTRACT 
Linden Ann Green 
HIV-1 Nef: therapeutic strategies and virological synapse-mediated infection 
HIV-1 infection is one of the greatest public health concerns today.  The current 
HIV/AIDS therapy is effective in halting virus multiplication and has improved the 
outlook of AIDS; however, high cost, side effects, and the rise of drug-resistant viral 
strains have posed challenges for long-term treatment and management and mandate 
development of alternative anti-HIV therapies.  Despite the fact that a great deal of 
progress has been made in our understanding of the infection over the last twenty-seven 
years, there are many unanswered basic scientific questions and no vaccines.  In this 
study, we focused on two aspects related to the HIV-1 protein Nef: one is development of 
a Nef-based anti-HIV therapeutic strategy; the other is discovery of a novel mechanism 
that accounts for Nef-enhanced viral infectivity. 
 
We first devised an anti-HIV therapeutic strategy that took advantage of the high virion 
incorporation of the Nef mutant Nef7 to deliver anti-HIV factors to the virion.  We 
performed a series of proof-of-concept experiments, using the host anti-HIV cellular 
factor APOBEC3G (A3G).  The Nef7.A3G fusion protein retains important properties of 
Nef7: higher virion incorporation efficiency, lack of PAK2 activation, and reduced CD4 
and MHC I downregulation, as well the anti-HIV infectivity function of A3G.  Moreover, 
virus-like particle (VLP)-mediated delivery of Nef7.A3G into infected CD4+ T 
lymphocytes leads to inhibition of HIV-1 replication in these cells.  These results support 
 v
the use of Nef7 as an anti-HIV therapeutic strategy for the delivery of therapeutic 
proteins into HIV-1 virions. 
 
HIV-1 Nef protein has long been known to enhance viral infectivity.  However, the 
underlying molecular mechanism remained elusive.  Here we show that Nef is important 
for VS formation and VS-mediated virus transmission from cell to cell, especially in 
primary cells.  Nef accomplishes this by inducing the clustering of VS components CD81 
and ZAP70 and by inducing formation of actin protrusions, and these functions involve 
specific and distinct Nef domains.  These findings not only yield new insights into the 
regulatory function of Nef in viral infectivity, but could also lead to development of more 
effective anti-HIV therapies that work equally well at blocking both VS-mediated and 
cell-free virus infection. 
 
 
       Johhny J. He, Ph.D., Chair
vi 
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INTRODUCTION 
 
1. HIV-1 AND AIDS EPIDEMIOLOGY 
1.1 HIV-1/AIDS epidemiology 
Human immunodeficiency virus type 1 (HIV-1) is the causative agent for acquired 
immune deficiency syndrome (AIDS), one of the greatest public health concerns in the 
world (www.unaids.org).  HIV-1 has caused a global pandemic that has resulted in over 
25 million deaths since it began in the early 1980s.  The most recent worldwide statistics 
reveal that as of the end of 2008, there were 33.4 million people living with HIV 
worldwide and approximately 2 million deaths in 2008 alone due to AIDS.  Of these, 
almost 75% were in sub-Saharan Africa where the availability of anti-retroviral drugs 
remains low, with less than 45% coverage of infected individuals.  In recent years the 
incidence of infection has decreased slightly, with only 2.7 million new cases in 2008 as 
compared to approximately 3.5 million in 1996; nevertheless, the overall number of cases 
is still increasing steadily due to both newly acquired infections and the increase of life 
expectancy due to anti-HIV treatment (www.who.int).  According to recent United 
Nations estimates, $25 billion will be needed to provide HIV treatment in low- and 
middle-income countries in 2010: an estimate that is $11.3 billion higher than what is 
currently available (www.uaids.org).  Despite the large amount of effort put into 
resolving it, the HIV pandemic remains a huge concern. 
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1.2 Clinical aspects of HIV-1 infection 
HIV-infected individuals usually experience an acute illness 2-4 weeks post-infection, 
described as flu-like (Fig. 1).  This typically lasts about 1-2 weeks and can involve a 
variety of symptoms such as fever, headache, gastrointestinal irritation, 
lymphadenopathy, weight loss, and myalgia (Hicks, Gay et al. 2007).  During this time, 
the virus seeds lymphoid organs such as lymph nodes and gut-associated lymphoid tissue 
(GALT) to establish a persistent infection (Fauci, Pantaleo et al. 1996).  The onset of 
symptoms corresponds with a high viral load, mainly produced from infected CD4+ 
CCR5+ T cells (Lyles, Munoz et al. 2000; Douek, Brenchley et al. 2002; Douek, Picker et 
al. 2003), and is accompanied by a sharp but transient decrease in the number of 
peripheral blood CD4+ T cells as well as a largely permanent decrease in gastrointestinal 
mucosal CD4+ CCR5+ memory T cells (Guadalupe, Reay et al. 2003; Brenchley, 
Schacker et al. 2004; Mehandru, Poles et al. 2004).  After a week or two the acute phase 
of infection passes, with resolution of the flu-like symptoms, a drop in viral load, and an 
associated rise in peripheral blood CD4+ T cells.  At this point, a chronic infection is 
established. 
 
The chronic phase is generally asymptomatic and is described as a period of clinical 
latency that lasts for an average of 10 years (Lyles, Munoz et al. 2000), although a small 
percentage of infected individuals known as long-term non-progressors exhibit no signs 
of disease progression even after 10 years or more, and without anti-retroviral treatment 
(Cao, Qin et al. 1995; Pantaleo, Menzo et al. 1995).  During this time viral titers exhibit a 
slow but steady increase, while peripheral blood CD4+ T cells decline steadily from the 
 3 
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Figure 1. Clinical course of HIV-1 infection.  Clinical, virological, and immunological 
course of a typical HIV-1-infected patient, illustrated as changes in HIV-1 plasma virus 
load (red) and peripheral blood CD4+ T cell counts (blue).  The X axis represent the time 
after primary infection, while the Y axis represents viral RNA copies in the plasma or 
CD4+ T cell counts.  Major events in disease progression are indicated.  Adapted from 
Grossman, Meier-Schellersheim et al. 2006. 
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small plateau reached after the partial recovery at the end of the acute illness (Blaak, de 
Wolf et al. 1997; Douek, Picker et al. 2003).  The immune system becomes continuously 
activated during this period, resulting in T cell exhaustion and further depletion of T cells 
(Leng, Borkow et al. 2001; Brenchley, Price et al. 2006).  Once the peripheral blood 
CD4+ T cell count falls below 200 cells/μl, usually accompanied by a sharp increase in 
viral load, the infected individual is considered to have AIDS (Pantaleo, Graziosi et al. 
1993).  This stage is characterized by the onset of AIDS-related opportunistic infections 
or tumors not found in immuno-competent people, such as Kaposi sarcoma and 
Toxoplasma Gondii infections. 
 
1.3 HIV-1  
HIV-1 is a complex retrovirus with a genome of about 10 kilobases in length.  The virion 
itself is approximately 120 nm in diameter and is comprised of a conical core containing 
a diploid RNA genome, which is in turn encapsulated by a membrane bilayer derived 
from the host cell membrane.  In addition to the gag, pol, and env genes that every 
retrovirus has, HIV-1 has 6 additional genes: vif, vpr, vpu, tat, rev, and nef.  These 9 open 
reading frames (ORF) result in fifteen proteins (Frankel and Young 1998).   
 
Gag encodes four structural proteins: matrix (MA), capsid (CA), nucleocapsid (NC), and 
p6, which comprise the virion core.  Env encodes one glycoprotein, gp160, which is then 
processed into gp120 and gp41 and is responsible for viral entry into the host cell 
(Hallenberger, Moulard et al. 1997).  Pol encodes a long polyprotein that is cleaved into 3 
essential enzymatic proteins, protease (PR), reverse transcriptase (RT), and integrase 
(IN), which are necessary for viral replication and are therefore encapsulated in the 
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virion.  Vpr is necessary for importation of the provirus to the nucleus in non-dividing 
cells and also causes cell cycle arrest (He, Choe et al. 1995).  Vpu increases the 
efficiency of viral budding from the host cell by inhibiting the activity of the host factor 
tetherin (Neil, Zang et al. 2008).  Tat is the transactivator of HIV and is required for 
efficient transcription of HIV mRNA (Berkhout, Silverman et al. 1989; Laspia, Rice et al. 
1989).  Rev provides nuclear export of non- or incompletely-spliced HIV mRNAs 
(Malim, Bohnlein et al. 1989; Malim, Hauber et al. 1989).  Vif abolishes the activity of a 
strongly anti-HIV host factor, APOBEC3G by inducing its ubiquitination (Mariani, Chen 
et al. 2003).  The remaining accessory protein, Nef, has numerous effector functions and 
will be discussed at greater length in subsequent sections. 
 
1.4 HIV-1 life cycle 
1.4.1 Entry 
The main cellular receptor of HIV-1 is CD4 (Sattentau and Weiss 1988).  The virus also 
has two co-receptors, CCR5 and CXCR4, at least one of which is required in addition to 
CD4 for viral entry into a host cell (Alkhatib, Broder et al. 1996; Alkhatib, Combadiere et 
al. 1996; Feng, Broder et al. 1996).  HIV-1 virions infect a susceptible cell by initially 
binding to CD4 via the HIV envelope glycoprotein gp120 (Fig. 2).  Following binding to 
CD4, gp120 undergoes a conformational change that allows it to also bind to the co-
receptors, either CXCR4 or CCR5.  Depending on the tropism of the virion, gp120 binds 
preferentially to either CCR5 or CXCR4.  Binding to the co-receptor induces an 
additional conformational change that exposes the gp41 glycoprotein that is needed for 
virus:cell fusion, thereby allowing the viral core to enter the cytoplasm  
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Figure 2. General overview of HIV-1 life cycle.  Important steps in HIV-1 life cycle are 
highlighted:  Binding of gp120 to CD4 and CCR5/CXCR4; fusion of the viral membrane 
with the cell membrane, resulting in virus penetration and uncoating of the core; reverse 
transcription of the ssRNA genome to dsDNA provirus; transport of the provirus to the 
nucleus and integration into the host chromosome; transcription of HIV-1 mRNA; 
translation of HIV proteins and viral assembly at the cell membrane; and finally, virion 
budding and maturation. 
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(Gallo, Finnegan et al. 2003).  CD4 is expressed on most white blood cells, and defines 
the main restriction  to viral entry.  CCR5 is expressed on resting T lymphocytes with the 
memory and effector phenotypes, monocytes, macrophages, and immature dendritic cells, 
and also on a number of cells in the central nervous system including neurons, astrocytes, 
and microglia (Blanpain, Libert et al. 2002).  CXCR4, on the other hand, is more 
widespread and expressed on a number of tissues, including hematopoietic and neuronal 
cells (Bleul, Wu et al. 1997; Rossi and Zlotnik 2000).  The expression profile of these co-
receptors reflects the tropism of HIV-1 during the course of infection.  CCR5 tropic 
viruses are the major transmissible form of the virus; as such, the initial infection is 
primarily in macrophages, dendritic cells, and CD4+ CCR5+ memory T cells (Scarlatti, 
Tresoldi et al. 1997).  The preference for CCR5 tropic viruses as the major transmissible 
form may help to establish the infection, as the cells these viruses infect are common 
reservoirs of HIV-1 in vivo.  As the infection progresses, the virus switches to a 
CCR5/CXCR4 tropic form, and finally to a CXCR4 tropic form (Clapham and McKnight 
2001).  The major cell target becomes T lymphocytes, resulting in an expanded tropism 
that reflects the more widespread expression of CXCR4 (Blaak, van't Wout et al. 2000; 
Douek, Picker et al. 2003). 
 
In addition to the classical CD4/co-receptor mediated entry, there a few non-standard 
receptors for HIV-1 that can enhance its binding to target cells although they do not 
mediate viral entry.  For instance, DC-SIGN (Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin), which is expressed on dendritic cells, can 
bind tightly to gp120, and then subsequently enhance the trans-infection of HIV-1 to T 
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cells (Geijtenbeek, Kwon et al. 2000; Lozach, Amara et al. 2004).  Likewise, the 
mannose-specific macrophage endocytosis receptor may enhance HIV-1 binding and 
entry into macrophages (Larkin, Childs et al. 1989; Hoffman, LaBranche et al. 1999; 
LaBranche, Hoffman et al. 1999; Liu, Liu et al. 2004).  HIV-1 gp120 also binds to the 
glycolipid galactocerebroside (GalC) and its sulphated derivative sulphatide, which are 
expressed on macrophages, colonic epithelial cells, and on neuronal and glial cells in the 
brain (Fantini, Cook et al. 1993). 
 
1.4.2 Reverse transcription and integration 
Following viral entry into the host cell the virus core is released, exposing a 
nucleoprotein complex containing MA, RT, IN, Vpr, Vif, Nef, and the diploid RNA 
genome.  The HIV-1 core also has additional incorporated proteins, including cellular 
proteins such as cyclophilin A and APOBEC3G when Vif is not expressed.  The genomic 
single-stranded RNA then undergoes reverse transcription to create a dsDNA molecule 
by utilizing the HIV-1 enzyme reverse transcriptase (Fig. 3).  RT is an extremely error-
prone enzyme, which results in the ability of HIV to rapidly mutate.  RT is comprised of 
three distinct enzymatic activities: an RNA-dependent DNA polymerase, an RNase H 
which degrades the DNA half of double-stranded DNA:RNA complexes, and a DNA-
dependent DNA polymerase.  Reverse transcription is initiated from a tRNA primer, 
which is packaged into the viral core and binds to the RNA genome at the primer binding 
site in its 5’ end.  Transcription commences using the RNA-dependent DNA polymerase 
activity until a DNA:RNA complex is formed.  The RNA half is then degraded by the 
RNase H activity and the tRNA primer jumps to the 5’ end of the newly synthesized  
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Figure 3.  Overview of HIV-1 reverse transcription.  A general schematic describing 
the process of HIV-1 reverse transcription: 1) Synthesis of the first section of minus 
strand DNA; 2) Degradation of the RNA portion of the DNA:RNA complex and template 
switching of the remaining DNA fragment; 3) Synthesis of the coding region of the 
minus strand DNA; 4) Degradation of most of the remaining RNA; 5) Synthesis of a 
portion of the positive strand DNA and degradation of the remaining RNA; 6) Template 
switching of the positive strand DNA fragment; 7) Filling in of the remaining gaps to 
create the dsDNA provirus.
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DNA molecule.  Transcription then finishes, with the DNA-dependent DNA polymerase 
completing the construction of a double-stranded DNA provirus.  Because of primer 
switching the ends of the RNA genome are duplicated, resulting in a flanking sequence 
known as the long-terminal repeat (LTR), which acts as the viral promoter (Basu, Song et 
al. 2008).  The full-length linear cDNA, which is considered the direct precursor of the 
provirus, decays rapidly if not integrated (Zhou, Zhang et al. 2005). 
 
The resulting dsDNA provirus forms a nucleic acid-protein complex known as the 
preintegration complex (PIC), which is comprised of the provirus, viral MA, Vpr, and IN.  
The PIC is imported to the nucleus via a nuclear localization sequence in IN, and is then 
incorporated into the host cell’s genome in a process that is enhanced by cellular 
activation.  Integration typically takes place in transcriptionally active regions of the host 
genome, particularly those having fewer GC-rich sequences (Lewinski, Yamashita et al. 
2006).  This may be in part due to the action of p75/LEDGF, a chromatin-associated 
protein that acts as a tethering factor for integrase (Vanegas, Llano et al. 2005; Llano, 
Vanegas et al. 2006).  The 3′-processing reaction involves the removal of two 
nucleotides, adjacent to a highly conserved CA sequence, from the 3′ end of both U3 and 
U5 viral LTR termini.  Next, the cleaved DNA is used as a substrate for strand transfer, 
resulting in the covalent insertion of the provirus into the cellular genome (Esposito and 
Craigie 1998; Wu, Li et al. 2005). 
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1.4.3 Transcription, splicing, and RNA export 
Once integrated, the provirus serves as a template for virus replication and mRNA 
transcription.  Initially, transcription proceeds at a basal level and is dependent upon the 
cellular transcription factors NFκB and AP2, which bind to the HIV LTR promoter 
(Harrich, Garcia et al. 1989; Perkins, Agranoff et al. 1994; Mallardo, Dragonetti et al. 
1996).  Viral transcripts produced at this point are short but contain the HIV-1 
transactivator Tat.  Tat interacts with the nascent viral mRNA through a stem-loop 
structure called TAR (Berkhout, Silverman et al. 1989) and recruits Cyclin T1 and CDK9 
to the TAR-Tat complex, resulting in phosphotylation of the RNAPII C terminal domain 
and generation of full-length HIV RNA transcripts (Mancebo, Lee et al. 1997; Zhu, 
Pe'ery et al. 1997).  The ability of HIV to replicate in peripheral blood lymphocytes is 
dependent upon induction of Cyclin T1 and CDK9 activity upon activation of the host 
cell, providing yet another reason why HIV requires host cell activation to replicate 
(Spina, Prince et al. 1997; Garriga, Peng et al. 1998; Flores, Lee et al. 1999). 
 
There are three types of HIV transcripts: unspliced, partially spliced, and completely 
spliced.  The completely spliced mRNAs include Tat, Rev, and Nef, and these are the 
first viral proteins made following HIV infection.  Since eukaryotic cells cannot export 
incompletely spliced or unspliced mRNAs from the nucleus (Zenklusen and Stutz 2001), 
once translated the HIV-1 protein Rev returns to the nucleus and acts to transport these 
mRNAs to the cytoplasm.  Rev first binds to the Rev-response element (RRE) present in 
unspliced mRNA transcripts (Malim, Bohnlein et al. 1989; Malim, Hauber et al. 1989).  
Rev then binds the chromosome maintenance gene 1 (CRM-1), which further recruits 
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Ran-GTP, resulting in the formation of a Rev-RRM-CRM-1-RanGFP complex.  This 
complex is able to be exported from the nucleus through nuclear pores utilizing a 
mechanism that requires hydrolysis of Ran-GTP to Ran-GDP (Askjaer, Jensen et al. 
1998).   
 
There are many cellular factors involved in the Rev-RNA nuclear export process, among 
them Sam68, hRIP, and DDX3.  DDX3 is a nuclear-cytoplasmic shuttling RNA helicase 
protein that localizes to nuclear pores (Yedavalli, Neuveut et al. 2004), while Rev-
interacting protein (hRIP) is proposed to be involved in the release of HIV-1 mRNA from 
the perinuclear region (Sanchez-Velar, Udofia et al. 2004; Yu, Sanchez-Velar et al. 
2005); both of these cellular factors are necessary for optimal HIV replication.  SRC-
associated protein during mitosis of 68kDa (Sam68) is absolutely required for Rev 
function (Li, Liu et al. 2002; Li, Liu et al. 2002; Modem, Badri et al. 2005).  It binds to 
both the RRE and Rev, and its down-modulation results in extensive accumulation of 
Rev-CRM-1 complexes in the nucleus, significantly inhibiting HIV replication (Li, Liu et 
al. 2002; Modem, Badri et al. 2005).  
 
1.4.4 Translation 
Translation of HIV-1 mRNA remains one of the least understood areas of the HIV 
lifecycle.  Due to mRNA splicing and processing, there are almost 30 distinct mRNA 
species produced from the HIV-1 provirus (Neumann, Harrison et al. 1994; Caputi, 
Freund et al. 2004).  These mRNA are each capped and polyadenylated, and share the 
first 289 non-coding nucleotides.  However, each mRNA species contains a unique 5’-
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untranslated region (5’UTR) that varies in length and secondary structure (Parkin, Cohen 
et al. 1988).  This may help regulate translation, but interestingly, the 5’UTR contains 
many highly conserved negative regulators of ribosomal scanning, such as TAR and the 
primer binding site (Geballe and Gray 1992; Berkhout 1996).  Consequently, HIV-1 
mRNA are not optimal substrates for cap-dependent translation.  This has led to the 
theory that HIV translation could be controlled through an internal ribosome entry site 
(IRES) (Buck, Shen et al. 2001; Yilmaz, Bolinger et al. 2006).  There have been 
conflicting reports in this area, with some studies showing an IRES in the 5’UTR and 
Gag coding sequences, and some studies that concluded there was no IRES present in 
unspliced HIV mRNA (Miele, Mouland et al. 1996; Brasey, Lopez-Lastra et al. 2003; 
Yilmaz, Bolinger et al. 2006).  The wide array of secondary structures in HIV-1 mRNA 
could potentially result in differential translation regulation due to specific interactions 
between cellular or viral proteins and mRNA structures.  For example, HIV-1 Gag 
inhibits its own translation at high concentrations by interacting with its 5’UTR 
(Anderson and Lever 2006).  Likewise, the HIV-1 Rev protein can inhibit general 
translation of HIV-1 proteins at high concentrations (Groom, Anderson et al. 2009) and 
several host proteins can also affect translation of HIV-1 mRNA (Bolinger and Boris-
Lawrie 2009). 
 
HIV-1 utilizes a number of strategies to regulate translation of specific viral proteins.  For 
example, the 5' UTR of both unspliced and spliced retroviral transcripts contain features 
that impede ribosomes scanning; this results in the ribosome skipping over a particular 
start codon and instead translating a different open reading frame (ORF) (Schwartz, 
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Felber et al. 1992; Anderson, Johnson et al. 2007).  Additionally, mRNA containing a 
combination of repetitive sequences and a stable secondary structure can momentarily 
halt ribosome movement, leading to an mRNA reading frameshift (Jacks, Power et al. 
1988; Gaudin, Mazauric et al. 2005). 
 
1.4.5 Virus assembly and budding 
The viral genomic RNA transcribed in the nucleus is exported to the cytoplasm.  The Env 
protein is produced in the endoplasmic reticulum as gp160 and transits through the Golgi 
apparatus to localize to lipid rafts in the cell membrane, while Gag is synthesized on free 
cytosolic ribosomes.  The Gag and Gag/Pol polyproteins once translated are transported 
to the intracellular face of lipid raft domains, possibly by utilizing the actin or 
microtubule network of the cell (Bieniasz 2009).  Once there, immature nucleocapsids 
form by capsid proteins assembling a shell around two copies of the full length viral 
RNA genome.  The immature virions bud from the cell surface, becoming encapsulated 
by a membrane derived from the lipid rafts, which contains the Env proteins as 
mentioned above (Ganser-Pornillos, Yeager et al. 2008; Ono 2009).  During the budding 
process protease cleaves the matrix protein, causing the virion to undergo a 
morphological change and become mature and infectious (Frankel and Young 1998).  In 
macrophages a similar process takes place, except the virions bud into large 
multivesicular bodies (MVB) inside the cell.  The MVB then fuses with the plasma 
membrane, releasing the virions contained within (Benaroch, Billard et al.). 
 
 
 18 
1.5 Current HIV-1 treatment 
1.5.1 HIV vaccines 
Initial efficacy trials on potential vaccines that attempted to produce antibody responses 
against gp120 failed, possibly due to the high variability in gp120 glycosylation patterns 
across different strains of HIV-1 (Derdeyn, Decker et al. 2004; Flynn, Forthal et al. 2005; 
Pitisuttithum, Gilbert et al. 2006).  Since attempts to elicit broad antibody responses 
proved difficult, there occurred a shift in focus towards the development of non-
protective vaccines that would elicit strong cellular immune responses.  These would not 
prevent acquisition of the infection, but would instead delay disease progression.  
However, recent attempts to develop this approach were met with failure in clinical trials 
(Steinbrook 2007).  Traditional ideas of vaccines do not appear to work in HIV infection; 
therefore, novel approaches must be conceived in order to create a workable HIV 
vaccine. 
 
1.5.2 HAART 
Despite the difficulties faced in the creation of an HIV vaccine, an effective therapy in 
the form of highly active anti-retroviral therapy (HAART) has resulted in a dramatically 
improved outlook for HIV-positive patients.  HAART has reduced the AIDS-associated 
mortality in developed countries by up to 80-90%, although the effect is much lower in 
developing countries where anti-retroviral drugs are cost-prohibitive and rare (Hammer, 
Eron et al. 2008; Ho and Bieniasz 2008).  Proper HAART application can reduce plasma 
viral loads to undetectable levels, but it cannot eradicate the virus.  Furthermore, 
replication can sometimes continue undetected in lymphoid tissues, and if treatment is 
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stopped for any reason viral loads become very high.  A HAART regimen consists of a 
combination of at least three different anti-retroviral drugs from at least two different 
categories.  These categories consist of reverse transcriptase inhibitors, protease 
inhibitors, and integrase inhibitors.  Most drugs, however, are in the first two categories, 
with only one integrase inhibitor currently approved (Table 1).   
 
Reverse transcriptase inhibitors can be nucleoside/nucleotide analogs or non-nucleoside 
analogs.  Nucleoside/nucleotide analogs act by terminating reverse transcription when 
they are incorporated into the newly synthesized DNA.  In contrast, non-nucleoside 
analogs block reverse transcriptase by binding to RT.  They are not incorporated into the 
viral DNA but instead inhibit the movement of protein domains needed to carry out the 
process of DNA synthesis.  Raltegravir, the lone integrase inhibitor, acts by inhibiting 
strand transfer during the integration process.  Protease inhibitors usually act by 
inhibiting the HIV-1 protease-dependent cleavage of the MA protein in immature virions, 
making sure that these virions never become mature and infectious.  In addition to these 
three types of anti-retroviral drugs, repeated attempts at developing entry and fusion 
inhibitors have been made (Deeks 2006).  Currently there are two approved by the Food 
and Drug Administration (FDA): Enfuvirtide targets gp41 to prevent fusion of the viral 
envelope to the cell membrane and Maraviroc, a CCR5 antagonist, prevents binding of 
gp120 to CCR5 (Simon, Ho et al. 2006).  These are not as universally effective as reverse 
transcriptase, integrase, and protease inhibitors, however, and are usually prescribed after 
the emergence of HIV-1 strains resistant to the more common treatments and 
administered in combination with other classes of antivirals (Rockstroh and Mauss 2004).  
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Table 1.  FDA-approved anti-HIV drugs 
Brand name Generic name Category 
Epivir 
Emtriva 
Retrovir 
Trizivir 
Zerit 
Ziagen 
Lamivudine 
Emtricitabine 
Zidovudine, azidotymidine 
Abacavir, zidovudine, lamivudine 
Stavudine 
Abacavir sulfate 
NRTI 
NRTI 
NRTI 
NRTI 
NRTI 
NRTI 
Intelence 
Rescriptor 
Sustive 
Viramune 
etravirine 
delavirdine 
efavirenz 
nevirapine 
NNRTI 
NNRTI 
NNRTI 
NNRTI 
Agenerase 
Crixivan 
Norvir 
Prezista 
Reyataz 
Amprenavir 
Indinavir 
Ritonavir 
Darunavir 
Atazanavir sulfate 
Protease inhibitor 
Protease inhibitor 
Protease inhibitor 
Protease inhibitor 
Protease inhibitor 
Fuzeon Enfuvirtide (T-20) Fusion inhibitor 
Isentress Raltegravir Integrase inhibitor 
Selzentry Maraviroc Binding inhibitor 
NRTI = nucleoside reverse transcriptase inhibitor 
NNRTI = non-nucleoside reverse transcriptase inhibitor 
         Data collected from FDA website www.fda.gov/oashi/aids/virals
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All of these treatments, however, share the common potential to become ineffective due 
to the rise of resistant viruses.  Unfortunately, the high cost of HAART and non-
compliance issues due to toxicity often contribute to the rise of HAART-resistant HIV-1 
strains.  This has made the development of alternative anti-HIV therapies a priority.  
Additionally, none of the current anti-HIV treatments involve the HIV-1 accessory 
proteins.  Since these proteins, especially Nef, can be expressed despite successful 
control of infection due to anti-retroviral therapy and contribute to disease progression, 
they make attractive targets for future therapy development (Fischer, Joos et al. 2004).  
Hence, this study focuses on the Nef protein. 
 
2. CELLULAR COFACTORS OF THE HIV LIFE CYCLE 
2.1 Positive cofactors 
The majority of cellular factors involved in the HIV-1 life cycle are positive factors that 
HIV utilizes to facilitate its replication (Table 2).  For example, TSG-101 is required for 
efficient virus budding (Hammarstedt and Garoff 2004).  The HIV-1 Gag p6 protein 
binds to TSG-101 and helps recruit additional components of the ESCRT-I, -II, and -III 
complexes (Demirov, Orenstein et al. 2002).  These complexes are part of the 
multivesicular body (MBV) pathway, which HIV-1 hijacks to bud from the cell.  There 
are also several cellular factors that HIV-1 utilizes to facilitate its transcription and post-
transcriptional processes.  Sam68, as mentioned above, is required for Rev-dependent 
export of singly spliced and unspliced viral mRNAs from the nucleus through its 
interaction with the Rev/CRM-1 complex.  Additionally, CyclinT1 is necessary for 
transcriptional elongation of HIV-1 transcripts from the LTR promoter (Price 2000)  
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      Table 2.  Major host factors involved in HIV-1 replication 
Host Factor Effect on HIV Step in life cycle affected 
APOBEC3G 
Tetherin 
REF-1 
TSG-101 
CyclophilinA 
LEDGF/p75 
ITK 
Cyclin T 
Sam68 
ESCRT complexes 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
reverse transcription 
budding 
uncoating? 
budding 
uncoating 
integration 
multiple steps 
transcription 
mRNA export 
virus assembly/budding 
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through its phosphorylation of the C-terminal domain of RNA polymerase II (Dahmus 
1996; Dahmus 1996).   
 
LEDGF/p75 stimulates nuclear localization and chromatin tethering for integrase, 
resulting in greater efficiency of proviral integration to the host chromosome (Llano, 
Vanegas et al. 2004; Llano, Vanegas et al. 2006).  Interactions of LEDGF/p75 with 
components of the general transcription machinery and the transcription activation 
domain of certain proteins indicate participation in transcriptional regulation, possibly in 
the induction of stress response genes (Cherepanov, Maertens et al. 2003).   
 
Inducible T cell kinase (ITK) is a Tec family tyrosine kinase that regulates T cell 
receptor-induced activation of PLCγ-1, Ca2+ mobilization and transcription factor 
activation, and actin rearrangement downstream of both TCR and chemokine receptors 
(Berg, Finkelstein et al. 2005).  Recently, ITK has been found to be important for 
multiple steps of the HIV-1 life cycle: upon gp120 binding to CXC R4 it induces actin 
reorganizations that facilitate virus entry, upregulating transcription factors in response to 
ITK signaling resulting in increased transcription from the HIV-1 LTR, and increases 
budding through protein interactions and membrane recruitment (Readinger, Schiralli et 
al. 2008).  The study of inhibitors for these and other pro-HIV cellular proteins is of 
growing interest, but care must be taken to ensure that inhibition of these proteins does 
not have a significant negative effect on the immune system or normal physiological 
function of the host. 
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2.2 Negative cofactors 
Because of the shortcomings of current anti-HIV therapies, there has recently been 
increased interest in exploiting cellular proteins involved in the HIV-1 lifecycle to 
develop new therapies.  Currently, there have been few negative regulators of HIV 
identified; among them are APOBEC3G (Simon, Gaddis et al. 1998; Sheehy, Gaddis et 
al. 2002), tetherin (Neil, Zang et al. 2008), and REF-1 (Towers, Bock et al. 2000).   
 
Tetherin is the term used to describe a cellular protein that prevents the release of certain 
enveloped virus particles and was identified to be the surface molecule CD317.  When 
expressed, it results in the retention of virions in intracellular vacuoles and at the cell 
surface.  The HIV-1 protein Vpu, however, downmodulates CD317/tetherin expression, 
allowing for the efficient release of viral particles (Neil, Zang et al. 2008).   
 
Restriction factor 1 (REF-1) acts to restrict HIV-1 infection at a point between virus entry 
and reverse transcription, most likely during uncoating (Braaten, Franke et al. 1996).  The 
mechanism REF-1 uses to do so is currently unknown, but seems to involve its 
interaction with the viral capsid.  However, the positive factor cyclophilin A, through its 
incorporation into HIV-1 virions, inhibits the activity of REF-1 presumably through 
blocking the interaction between REF-1 and p24 (Towers, Hatziioannou et al. 2003).   
 
The final anti-HIV cellular factor discovered so far is APOBEC3G, which will the 
covered in depth in the following section.  These host factors appear to be part of an 
innate antiviral defense system which, if manipulated correctly, may be utilized in the 
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construction of novel anti-HIV therapies that have a lower risk of developing resistant 
viral strains than current treatments. 
 
3. APOBEC3G 
3.1 APOBEC family 
The APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) 
superfamily is a large family of tissue-specific cytidine deaminases that display RNA-
editing or DNA mutation abilities.  It includes APOBEC1, APOBEC2, APOBEC3, and 
AID (Teng, Ochsner et al. 1999; Harris, Petersen-Mahrt et al. 2002; Jarmuz, Chester et al. 
2002).  APOBEC1, the prototypic enzyme of the family, is the key component of an 
RNA editing complex that deaminates cytosines in mammalian apolipoprotein B mRNA, 
resulting in a truncated form of apoB (Chester, Weinreb et al. 2004).  AID (activation-
induced cytidine deaminase) was the second family member to have its function 
identified and is the enzyme responsible for producing somatic hypermutations in 
immunoglobulins leading to antibody diversification during B cell development 
(Muramatsu, Kinoshita et al. 2000; Revy, Muto et al. 2000).  APOBEC3 family members 
have been shown to have extensive anti-viral activities, suggesting that this family also 
plays an important role in innate immunity (Bishop, Holmes et al. 2004).  There are a 
number of APOBEC3 proteins, which are expressed in a tissue-specific manner.  For 
example, APOBEC3G, -3F, and -3C are expressed in spleen, ovary, testes, and peripheral 
blood lymphocytes, while APOBEC3B, -3C, and to a lesser extent -3A are prevalent in 
various cancer tissues (Jarmuz, Chester et al. 2002; Bishop, Holmes et al. 2004).   
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3.2 APOBEC3G 
APOBEC3G (or A3G) is a cellular anti-HIV protein that restricts HIV replication at the 
stage of reverse transcription.  It was discovered to be the factor that restricted HIV∆vif 
replication in non-permissive cell lines (Simon, Gaddis et al. 1998; Sheehy, Gaddis et al. 
2002).  There is evidence that A3G may also restrict other viruses such as hepatitis B 
virus (HBV) as well as endogenous retroelements such as long terminal repeat (LTR) 
retrotransposons (Cullen 2006).  A3G is a ss DNA cytidine deaminase of ~42 kDa that 
deaminates C→U on the proviral minus strand of HIV during reverse transcription, 
resulting in G→A hypermutations in the finished provirus (Harris, Bishop et al. 2003; 
Aguiar and Peterlin 2008).  These mutations may have many consequences: 1) Cellular 
DNA repair enzymes such as uracil DNA glycosylase may attempt to repair the provirus, 
resulting in its degradation; 2) The hypermutation of the provirus may result in a non-
functional LTR, thus impairing the ability of the provirus to integrate into the host 
genome and resulting in its degradation; or 3) The provirus manages to integrate into the 
host genome, but the large number of mutations results in a non-functional promoter or 
defective viral proteins (Fig. 4).  Since the activity of A3G takes place during reverse 
transcription within the HIV-1 capsid, isolated from the cytoplasm and all other host 
cellular factors, it is essential for the function of A3G that it incorporates into virions.  
During HIV∆vif replication A3G is incorporated into progeny virions via interactions 
with the HIV-1 nucleocapsid protein, thus allowing A3G to be present for reverse 
transcription.  When those virions infect a second cell, A3G renders them non-replicative.  
However, A3G does not affect WT HIV replication because of the antagonistic effect of 
Vif.  Vif binds to A3G and recruits the E3 ubiquitin ligase cullin 5-elongin B/C 
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Figure 4.  APOBEC3G function during HIV-1 replication.  A schematic 
representation of the anti-viral function of APOBEC3G and its interaction with HIV-1 
Vif.  When Vif is not expressed, A3G is incorporated into progeny virions and is present 
in the secondary infection during reverse transcription where it induces deleterious 
hypermutations, preventing successful replication.  When Vif is present, it induces 
ubiquitination of A3G, preventing its incorporation into progeny virions and allowing 
secondary infections to proceed unimpeded.  
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(Mehle, Goncalves et al. 2004).  This targets A3G for ubiquitination and subsequent 
degradation by the proteosome, thus decreasing the available pool of A3G and limiting its 
incorporation into virions, and abolishing its ability to restrict HIV infection (Marin, Rose 
et al. 2003; Huthoff and Malim 2007). 
 
4. NEF 
4.1 Nef expression and structure 
Nef is an accessory protein of ~27 kDa.  It is post-translationally modified by 
phosphorylation and by the addition of a myristoyl moiety to its second amino acid 
(glycine), which aids in its membrane targeting and is required for most Nef functions 
(Fig. 5).  The nef gene is found at the 3’ end of the HIV genome, partially overlapping 
the 3’ LTR (Foster and Garcia 2007; Raney, Shaw et al. 2007).  While Nef primary 
sequences can vary, structurally Nef is well conserved with an N-terminal flexible 
disordered region, followed by a well-structured, globular core domain, and then a short 
C-terminal flexible domain (Arold and Baur 2001; Roeth and Collins 2006).  One of the 
most important motifs for Nef function is the SH3 domain-binding sequence (PxxP) that 
is located in the globular core domain and is responsible for Nef binding to many SH3-
domain-containing proteins, such as Src, Lck, and Hck and subsequent modulation of 
their kinase activities.  Other important Nef residues include an N-terminal stretch of 
basic residues that can contribute to Nef membrane localization, an acidic region 
(62EEEE65) that is responsible for Nef perinuclear localization, and three pairs of amino 
acid residues (W57/L58, L164/L165, and D174/D175) that act to alter the surface expression of 
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Figure 5.  Functional domains and important residues of HIV-1 Nef.  Important Nef 
residues are labeled above the figure, with the corresponding function below. 
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many cellular proteins by serving as a bridge to protein sorting pathways (Geyer, Fackler 
et al. 2001). 
 
4.2 Nef importance during HIV infection 
While Nef is dispensable for in vitro replication of HIV-1, it is absolutely essential for 
efficient viral spread in vivo.  It is the single most important HIV pathogenic factor, and 
is responsible for T cell activation and the establishment of a permissive replicative 
environment.  It has been found that deletion of Nef significantly reduces the pathology 
observed in SIV-infected Rhesus Macaques (Kestler, Ringler et al. 1991).  Additionally, 
HIV-1 isolates that contain defective Nef alleles have been found to correlate with long-
term non-progressors, i.e. HIV-infected individuals who have had the virus for ten or 
more years without developing AIDS (Chowers, Spina et al. 1994; Spina, Kwoh et al. 
1994; Kirchhoff, Greenough et al. 1995; Salvi, Garbuglia et al. 1998).  
 
Nef has no intrinsic enzymatic activity, but instead functions through interactions with 
cellular components.  Over thirty putative Nef binding targets have been identified, and 
the number is still growing.  It has been hypothesized that the great variety of Nef 
functions can be attributed to the large stretches of flexible, disordered regions mentioned 
above, as Nef could then potentially adopt different conformations depending on its 
binding partner, resulting in seemingly contradictory functions within the infected cell 
(Arold and Baur 2001).  While Nef has numerous effector functions, they can be broadly 
separated into three categories: 1) Alteration of protein trafficking, especially in the 
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context of the downregulation of surface receptors; 2) Alterations in cell signaling 
cascades; and 3) Enhancement of HIV-1 infectivity. 
 
4.3 Nef functions during HIV infection 
4.3.1 Alteration of surface receptors 
The list of proteins affected by Nef has continued to grow over the past several years.  To 
date, Nef has been reported to decrease the cell surface expression of CD4, MHC I, 
CD28, NKG2D, CXCR4, and CD80 among others (Garcia and Miller 1991; Anderson, 
Lenburg et al. 1994; Foster, Anderson et al. 1994; Schwartz, Marechal et al. 1996; 
Swigut, Shohdy et al. 2001; Keppler, Tibroni et al. 2006; Venzke, Michel et al. 2006).  
Additionally, Nef alters the subcellular localization of other proteins, such as 
sequestering recycling TCR-CD3 complexes and the Src kinase Lck with endosomes 
(Ehrlich, Ebert et al. 2002; Haller, Rauch et al. 2007).  Not all of the mechanisms by 
which Nef affects these proteins have been fully elucidated, but in most cases Nef acts as 
a bridge between the targeted molecule and intracellular trafficking proteins.  Nef is 
known to interact with many such proteins, including adaptor protein complexes AP-1, -
2, and -3, PACS-1, and COP-I concatemers (Roeth and Collins 2006).  
 
4.3.2 Alteration of intracellular signaling pathways 
Nef accomplishes many of its pathogenic functions by interfering with cellular signaling 
cascades, such as PAK2-induced alteration of the actin cytoskeleton (Khan, Sawai et al. 
1998; Manninen, Renkema et al. 2000; Renkema and Saksela 2000; Greenway, Holloway 
et al. 2003; Wei, Arora et al. 2005).  For example, Nef can induce rapid and transient 
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phosphorylation of the α and ß subunits of the IκB kinase complex and of JNK, ERK1/2, 
and p38 mitogen-activated protein kinase family members among others (Mangino, 
Percario et al. 2007).  Nef also modulates the TCR signaling cascade to provide a balance 
between the T cell activation required for efficient HIV-1 replication and the apoptosis 
that occurs if T cells are overly activated, which would limit the ability of infected cells 
to produce virus.  It has been proposed that Nef accomplishes this by inducing 
endogenous activation of T cells while at the same time repressing exogenous activation 
(Fackler, Alcover et al. 2007).  In addition to these effects in infected cells, Nef also has 
significant effects on bystander cells, such as inducing maturation of dendritic cells, 
apoptosis of uninfected T cells, and suppression of CD40-dependent immunoglobulin 
class switching in B cells (Qiao, He et al. 2006; Quaranta, Mattioli et al. 2006). 
 
4.3.3 Enhancement of infectivity 
One of the most elusive activities of Nef is its ability to enhance the infectivity of HIV in 
primary cells and some T cell lines.  Although there is generally no change in HIV-1 
replication kinetics with or without Nef in vitro, Nef-defective HIV-1 exhibits greatly 
decreased replication in primary cells.  The finding that Nef-containing viral particles 
were at least 10 times more infectious than Nef-deleted viruses in single-round infectivity 
assays partially explains this difference in replication (de Ronde, Klaver et al. 1992; 
Miller, Warmerdam et al. 1994; Spina, Kwoh et al. 1994).  This Nef phenotype was 
observed over ten years ago, but the mechanism by which Nef achieves this enhancement 
has never been conclusively established.  Enhancement of infectivity is dependent on the 
presence of Nef in the virus-producing cell, and is determined by virion incorporation of 
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Nef (Welker, Harris et al. 1998).  Nef-containing viruses resemble Nef-defective viruses 
both structurally and biochemically, and they both fuse efficiently with cells (Tobiume, 
Lineberger et al. 2003; Cavrois, Neidleman et al. 2004; Day, Munk et al. 2004).  
However, Nef-defective viruses exhibit decreased reverse transcription in target cells 
despite containing normal levels of viral genomic RNA and active reverse transcriptase 
(Chowers, Spina et al. 1994; Aiken and Trono 1995; Schwartz, Marechal et al. 1995). 
 
An attractive recent hypothesis is that Nef acts to remodel the cortical actin barrier to 
allow the viral core to penetrate into the cytoplasm (Chazal, Singer et al. 2001).  This 
hypothesis is supported by the finding that virions that are pseudotyped with pH-
dependent envelope proteins that function by endocytosis of the virion, such as VSV-G, 
do not require Nef while pH-independent envelope proteins that fuse at the plasma 
membrane, such as that of HIV-1, do require Nef.  In addition, disruption of the actin 
cytoskeleton in target cells compensates for the absence of Nef during infection only 
when virus enters the cell by membrane fusion but not when entry is by endocytosis 
(Campbell, Nunez et al. 2004).  This theory may explain the increased infectivity of cell-
free HIV-1 virions; however, increased cell-free viral infectivity may not completely 
explain the greatly increased replication kinetics of WT HIV over Nef-deleted viruses in 
primary cells. 
 
4.4 Nef7 
Recently a mutant of Nef known as Nef7 was characterized by the Federico laboratory in 
Italy.  Nef7 is derived from the Nef allele of F12-HIV, a non-producing strain of HIV-1 
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that was cloned from Hut-78 cells previously infected with the supernatant of the 
peripheral blood lymphocytes (PBL) of an HIV seropositive patient (Carlini, Nicolini et 
al. 1996).  In an attempt to discover the reasons behind the failure of F12-HIV to produce 
even aberrant HIV-1 particles they discovered that its gag, vif, and nef genes were all 
highly defective (D'Aloja, Olivetta et al. 1998).  The F12-HIVnef allele contained three 
rare point mutations: E140G, V153L, and E177G, and blocked the replication of the highly 
productive NL4-3 HIV-1 strain at the level of virus assembly or release.   
 
As part of an attempt to determine the importance of these mutations the Federico 
laboratory created a Nef mutant they termed Nef7 which retained two of the three point 
mutations: V153L, and E177G.  Nef7 retained most of the properties of F12-HIVnef in that 
it was much less pathogenic than WT Nef.  Nef7 was defective for many characteristic 
Nef functions, such as PAK2 activation, MHC I and CD4 down-regulation, and binding 
to the V1H regulatory subunit of the vacuolar ATPase (D'Aloja, Santarcangelo et al. 
2001; Peretti, Schiavoni et al. 2005).  It is important to note that Nef7 may be defective 
for other Nef properties, as these were the only phenotypes tested.  Another property of 
Nef7 that distinguishes it from WT Nef is its incorporation into virions.  Nef normally 
incorporates into progeny virions at the rate of <10 molecules per virion.  Nef7, on the 
other hand, incorporates an estimate of up to1100 Nef molecules per virion.  This 
increased virion incorporation does not rely on HIV-specific components, as Nef7 also 
shows increased incorporation into murine leukemia virus (MLV) virions and virus-like 
particles (VLP).  Nef7 incorporation into virions correlates well with its increased lipid 
raft localization (Peretti, Schiavoni et al. 2005).  This likely explains why other viral 
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components are unnecessary; HIV and MLV both bud from lipid rafts, and the presence 
of increased levels of Nef7 in lipid rafts would allow more incorporation into virions. 
 
One other important finding concerning Nef7 was that C-terminal fusion of proteins did 
not affect its virion incorporation.  Both GFP and thymidine kinase (TK) C-terminal 
fusion proteins have been stably expressed, and their virion incorporation was not 
significantly affected (Peretti, Schiavoni et al. 2006).  Because of this, and because of its 
less pathogenic properties, Nef7 shows great promise as a carrier protein for therapeutics 
that target components of the HIV virion or lipid rafts.  Testing this potential is the focus 
of part of this thesis. 
 
5. TRANSIENT T CELL INTERACTIONS  
5.1 Immunological synapses 
5.1.1 Structure and function of immunological synapses 
The term “immunological synapse” (IS) refers to close cell-cell contacts between an 
antigen-presenting cell (APC) and T-lymphocytes that typically lead to the activation of 
the lymphocyte.  Initial engagement of the T-cell receptor (TCR) on the lymphocyte with 
peptide-loaded MHC II molecules on the APC leads to rapid reorganization of plasma 
membrane lipids, surface receptors, and components associated with the inner leaflet of 
the plasma membrane.  IS components are recruited to membrane microdomains, either 
from dispersed regions of the plasma membrane or from intracellular compartments, 
while TCR-inhibitory components are excluded (Huppa and Davis 2003; Friedl, den Boer 
et al. 2005; Saito and Yokosuka 2006).  Immunological synapses form a structure that 
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can be visualized microscopically, and generally resembles a bulls eye (Fig. 6).  The 
central ring, or central supramolecular activation complex (cSMAC), consists of the 
TCR/CD3, CD28, and PKCθ.  Surrounding the center is the peripheral supramolecular 
activation complex (pSMAC), which consists mainly of adhesion molecules such as 
ICAM-1 and LFA-1 that help to stabilize the interaction between the T-cell and APC 
(Monks, Freiberg et al. 1998; Grakoui, Bromley et al. 1999). 
 
The formation of an IS allows for fast and potent mounting of a signaling response that 
includes a cascade of tyrosine phosphorylation, release of Ca2+, and activation of target 
genes, such as IL-2 (Bunnell, Hong et al. 2002; Barda-Saad, Braiman et al. 2005; Campi, 
Varma et al. 2005).  Importantly, continuous activation of T cells via the TCR results in 
apoptotic cell death, creating a need for negative regulation of the IS.  Consequently, 
following successful signal initiation the IS is down-modulated.  This mainly occurs via 
the endocytosis of the TCR and associated proximal machinery, and results in the 
dissociation of IS components (von Essen, Bonefeld et al. 2004; Varma, Campi et al. 
2006; Krammer, Arnold et al. 2007).  
 
5.1.2 Nef involvement in the immunological synapse 
HIV-1 replication in primary human CD4+ T lymphocytes is strictly coupled to the 
activation state of these cells; while virus entry is unhampered in unactivated cells, 
subsequent steps of the viral life cycle are only supported during activation, as mentioned 
above (Stevenson 2003).  However, while a minimal degree of activation is a prerequisite 
for efficient HIV-1 spread, full and sustained activation may shorten the life span 
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Figure 6.  Schematic of the immunological synapse.  The IS forms between an APC 
and a CD4+ T cell.  A.  When viewed from above, the IS forms a bulls-eye structure with 
the cSMAC in the middle surrounded by the pSMAC.  B.  Components of the cSMAC, 
including TCR/CD3, CD28, and PKCθ, are recruited to the center of the IS in an actin-
dependent manner.  Adhesion molecules stabilize the connection utilizing a second actin-
dependent pathway.  Engagement of the TCR results in stimulation of the T cell, as 
shown by increased Ca2+ levels and activation of transcription factors such as NFAT, 
NFκB, and AP1. 
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of an infected cell, thereby reducing the release of progeny viruses.  Therefore, HIV-1 
would ideally require a means to provide partial activation of T cells while preventing 
apoptosis due to excessive activation (Zhang, Schuler et al. 1999; Haase 2005). 
 
Multiple effects of HIV-1 on IS organization and formation have been reported 
(Thoulouze, Sol-Foulon et al. 2006; Fackler, Alcover et al. 2007), many of which have 
been attributed to Nef.  Firstly, Nef has profound effects on protein sorting at the IS.  
Once TCR/CD3 has been internalized following initial IS stimulation, Nef retains it in the 
recycling endosomes, thus preventing further activation.  Nef also retains the proximal 
signaling kinase Lck in recycling endosomes, further preventing prolonged signaling 
through the IS (Haller, Rauch et al. 2007).  Secondly, Nef interferes with maturation of 
the IS.  Initial receptor engagement and signaling are unaffected in Nef-expressing cells, 
while later stages of IS signaling are inhibited.  This is thought to occur by means of Nef 
preventing the translocalization of the actin regulator N-Wasp to the cell periphery, 
thereby inhibiting cell spreading and late stage tyrosine phosphorylation (Haller, Rauch et 
al. 2006).  In contrast to these negative effects on IS function, Nef enhances signaling 
cascades downstream of the IS (Fenard, Yonemoto et al. 2005).  Late activation events, 
such as IL-2 production, NF-AT activation, and NFκB activation, are all enhanced in 
Nef-expressing cells resulting in increased T cell activation.  In addition to inducing T 
cell activation, IL-2 is also pro-proliferative for T cells which could increase the number 
of target cells available for HIV-1 infection.  This combination of Nef effects may confer 
an advantage to HIV-1 by allowing minimal stimulation while preventing apoptosis.  
 42 
This process might also favor the development of quiescent, latently infected 
lymphocytes. 
 
5.2 Virological synapses 
5.2.1 Types of virological synapses 
For decades cell-to-cell transmission of retroviruses has been intermittently described in 
the literature (Yamamoto, Okada et al. 1982; Popovic, Lange-Wantzin et al. 1983; 
Okochi, Sato et al. 1984; Sato, Orenstein et al. 1992; Johnson and Huber 2002).  
However, it was never fully explored until the description of an immunological synapse-
like structure in HTLV-infected T lymphocytes that exhibited accumulation of the 
HTLV-1 core protein Gag and the HTLV-1 genome at the cell-cell junction (Igakura, 
Stinchcombe et al. 2003).  The structure was termed a “virological synapse” due to its 
physical similarity to the immunological synapse and has since been described in HIV 
and murine leukemia virus (MLV) infections (Sherer, Lehmann et al. 2007).  Much of 
what is known about cell-to-cell infection is inferred from microscopic image analysis; 
fluorescence microscopy shows accumulation of viral proteins at the cell-cell contact 
sites and electron microscopy shows virus particles localized between interacting cells 
(Igakura, Stinchcombe et al. 2003; Majorovits, Nejmeddine et al. 2008).  In the case of 
HTLV-1, cytoskeletal reorganization at the VS is promoted by the viral protein Tax 
(Nejmeddine, Barnard et al. 2005; Nejmeddine, Negi et al. 2009); and utilizes the host 
scaffolding protein Dlg to stabilize contacts via interactions with the C-terminus of the 
cytoplasmic domain of HTLV-1 Gag (Blot, Delamarre et al. 2004). 
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In contrast with the strictly T cell-T cell VS used in HTLV-1 infections, HIV-1 can 
induce VS formation in a variety of cell types.  Virological synapses have been reported 
between dendritic cells and T cells (McDonald, Wu et al. 2003) and macrophages and T 
cells (Carr, Hocking et al. 1999; Groot, Welsch et al. 2008) as well as between T cells 
alone.  These differing cell types may or may not result in different requirement for VS 
formation and cell-cell transfer of virus.   
 
In addition to virological synapses, there exists a second means of direct cell-cell spread 
of HIV-1.  These are more long-range, and are known as nanotubes or filopodial bridges 
(Sherer, Lehmann et al. 2007; Davis and Sowinski 2008; Sowinski, Jolly et al. 2008).  It 
has been hypothesized that these protrusions are remnants of virological synapses, left 
after cell separation, or that they are the initial step in VS formation, establishing cell-cell 
connections that allow the infected and uninfected pair to come together more efficiently 
(Haller and Fackler 2008).   
 
5.2.2 HIV transfer through T cell virological synapses  
Viral spread through virological synapses is now thought to be the main route of HIV-1 
transmission, particularly in environments with close cellular contacts, such as peripheral 
lymph nodes and gut associated lymphoid tissue (GALT) (Phillips 1994; Haase 1999).  
Because viruses can pass directly between cells during VS formation instead of budding 
from infected cells and diffusing until a susceptible target cell is encountered, viral spread 
through VS is much quicker and more efficient than cell-free viral spread (Chen, Hubner 
et al. 2007; Sourisseau, Sol-Foulon et al. 2007).  Indeed, one infected T cell can form 
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multiple synapses with target cells, thus ensuring an even faster rate of viral spread 
(Rudnicka, Feldmann et al. 2009).  However, the HIV-1 VS has not been as well 
characterized as the HTLV-1 VS.  Assembly of the VS requires engagement of the HIV 
Env surface subunit gp120 expressed on the effector cell, with its cellular receptors CD4 
and CXCR4 on the target cell (Fais, Capobianchi et al. 1995; McDonald, Wu et al. 2003).  
Further recruitment of receptors and HIV-1 proteins to the conjugate interface is a 
cytoskeleton-dependent process in both target and effector T cells (Iyengar, Hildreth et al. 
1998; Jolly, Mitar et al. 2007).  Known components of the VS include leukocyte 
function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 and 3 
(ICAM-1/3) (Jolly, Mitar et al. 2007), along with ZAP-70 tyrosine kinase (Sol-Foulon, 
Sourisseau et al. 2007) (Fig. 7).  Once the VS forms, HIV cores can be directly 
transferred to the target cell where they will undergo reverse transcription.  Viral particles 
then specifically bud at the synapse and are taken up into target cells (Chen, Hubner et al. 
2007; Bosch, Grigorov et al. 2008), which may be assisted by the formation of an F-
actin-depleted zone in the target cell (Vasiliver-Shamis, Cho et al. 2009).   
 
Microscopically, virological synapses can be identified by the clustering of VS 
components such as gp120, CD4, and p24 at the site of contact between an infected and 
an uninfected cell (Jolly, Kashefi et al. 2004; Jolly and Sattentau 2004).  As compared to 
the immunological synapse, very little is known about the cellular or viral proteins that 
regulate the HIV-1 virological synapse.  Aside from the requirement of gp120, nothing is 
known of the contribution of HIV-1 proteins to VS formation.  Likewise, the only known 
cellular components of the VS are adhesion molecules, the HIV-1 receptors, and one 
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Figure 7.  Schematic of the known components of the HIV-1 virological synapse.  
The VS forms between an infected cell expressing gp120 and an uninfected target cell 
expressing CD4.  Synapse components are recruited to the contact site in an actin-
dependent manner.  Adhesion molecules stabilize the connection, and provide some 
signaling to the actin pathways that promote VS formation.  ZAP70 acts to increase the 
transfer of HIV virions to the target cell by an unknown mechanism, likely involving 
actin.  Actin reorganization is required for recruitment of synapse components, viral 
transfer, and conjugate formation through adhesion molecules.
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tyrosine kinase, ZAP70 (Sol-Foulon, Sourisseau et al. 2007).  VS formation is dependent 
upon actin polymerization and requires lipid raft integrity in order to remain stabilized 
(Jolly and Sattentau 2005), but the regulators of both actin polymerization and lipid raft 
clustering are unknown.  The mechanisms behind HIV-1 VS formation and viral transfer 
are important aspects of the HIV-1 life cycle.  Furthermore, understanding of these 
mechanisms is useful in the development of new anti-HIV therapies particularly given the 
importance of VS-mediated HIV-1 transfer in vivo. 
 
6. LIPID RAFTS 
6.1 Composition and function  
Lipid rafts are small detergent-resistant domains of the cell membrane, rich in 
sphingolipids and cholesterol in the outer membrane leaflet, connected to largely 
saturated phospholipids and cholesterol in the inner membrane leaflet.  These assemblies 
are fluid, but more tightly packed and ordered than the surrounding bilayer due to the 
presence of a greater amount of saturated phospholipids as compared to the unsaturated 
lipids found in non-raft membranes (Brown and London 1998).  Rafts are mainly present 
in apical plasma membrane domains, but are also present in lower concentrations in the 
basolateral plasma membrane and on Golgi and trans-Golgi membranes (Simons and 
Ikonen 1997; Brown and London 1998; Brown and London 2000).  They play an 
essential role in signal transduction and cell activation.  Many signaling proteins such as 
MHC I and II, CD3, and annexin localize to lipid rafts; these proteins are usually isolated 
in small, dynamic rafts.  Upon stimulation, the small dynamic rafts cluster into larger 
platforms with sustained signal transduction (Harder, Scheiffele et al. 1998; Janes, Ley et 
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al. 1999).  Aggregation of raft-associated proteins, either initiated by binding of ligands 
or antibody-mediated cross-linking, can recruit new proteins to raft regions to create a 
signaling complex; for example, the immunological synapse (Dykstra, Cherukuri et al. 
2003; Gupta and DeFranco 2003; Horejsi 2003).   
 
6.2 Lipid rafts during HIV infection 
HIV-1 utilizes lipid rafts for nearly all steps of its life cycle.  Immediately following 
exposure the virus must pass through mucosal tissue in order to reach its cellular target; 
this epithelial transcytosis is dependent upon the formation of lipid rafts in the epithelial 
cells (Alfsen, Iniguez et al. 2001).  Likewise, entry into permissive target CD4+ T cells or 
macrophages requires clustering of lipid rafts, as the HIV-1 receptors localize to rafts and 
binding can be partially affected by the removal of cholesterol and thus destabilization of 
lipid rafts (Fantini, Hammache et al. 2000; Fantini, Maresca et al. 2000; Hammache, 
Pieroni et al. 2000; Manes, del Real et al. 2000).  Finally, virus assembly and budding 
take place from lipid rafts (Nguyen and Hildreth 2000).  This selective budding allows 
both the specific exclusion of host proteins that could negatively affect virus propagation 
or survival, and the inclusion of specific host membrane-associated proteins and lipids 
into the virion that are able to deregulate cellular and humoral immune responses (Frank, 
Stoiber et al. 1996; Cantin, Fortin et al. 1997; Peterlin and Trono 2003; Wilfingseder, 
Spruth et al. 2003).   
 
The final, and extremely important, function of lipid rafts in the HIV-1 life cycle involves 
alteration of signaling mechanisms in the host cell for efficient replication and immune 
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evasion.  The virus starts hijacking cellular signaling machinery immediately upon 
binding, when gp120 interaction with CD4-p56lck complexes in lipid rafts to activate a 
variety of signaling pathways, including PKC, Ras, ERK1/2, and MAPKs (Tamma, 
Chirmule et al. 1997; Briant, Robert-Hebmann et al. 1998).  However, Nef exhibits by far 
the most interactions with raft-associated proteins.  The highly conserved PxxP sequence 
binds to the SH3 domain of a variety of raft-associated molecules, including Src family 
kinases, PKC, PAK2, and Vav (Renkema and Saksela 2000).  Furthermore, Nef can 
induce the activation of these molecules even in the absence of stimulation (Schrager, 
Der Minassian et al. 2002).  However, it has been shown that upon T cell activation, 5-
10% of the Nef cellular pool localizes to lipid rafts (Fenard, Yonemoto et al. 2005).  Nef 
localization to lipid rafts is likely a key aspect of many of its functions.  For instance, 
activation of PAK2 by Nef requires its localization to lipid rafts, where it interacts with 
Vav to activate PAK2 upstream regulators Cdc42 and Rac (Lu, Wu et al. 1996; Fackler, 
Luo et al. 1999; Rauch, Pulkkinen et al. 2008).  Additionally, in Nef-expressing CD4+ T 
cells UbcH7, an E2 ubiquitin-conjugating enzyme that acts as a negative regulator of 
signaling, is absent from lipid rafts.  Exclusion of UbcH7 from rafts would result in 
accumulation of tyrosine-phosphorylated Vav and a subsequent increase in Cdc42 
activity (Miura-Shimura, Duan et al. 2003; Simmons, Gangadharan et al. 2005).  In 
addition to decreasing negative regulators of signaling, Nef can also increase the levels of 
signaling in lipid rafts by increasing the amount of signaling molecules within rafts as 
well as promoting the fusion of lipid rafts into the larger rafts required for sustained 
signaling (Djordjevic, Schibeci et al. 2004).    
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Summary of the background and our hypothesis 
Despite the overall success of HAART in reducing viral replication and prolonging the 
lifespan of HIV-infected individuals, multi-drug resistance, high cost, and toxicity remain 
a major concern.  Therefore, the development of novel therapeutic strategies is a priority.  
Moreover, with the realization of the importance of virological synapses to the spread of 
HIV-1, the development of new therapies should take into account the differing 
requirements of cell-free and cell-cell infections.   
 
The first part of this work addressed the search for novel anti-HIV therapies.  
Collectively, the unique properties of Nef7 offer it as a potentially novel and non-toxic 
carrier platform to deliver therapeutic proteins into HIV-1 virions, inactivate virions, and 
subsequently block HIV-1 replication.  Thus, we hypothesized that the high virion 
incorporation of Nef7 in the context of the Nef7.A3G fusion protein would override Vif-
targeted A3G degradation and as a result, restore the anti-HIV phenotype of A3G.   
 
The second part of this work addressed the formation of the HIV-1 virological synapse.  
In order for new potential therapies to take into account the differing requirements of 
cell-free and cell-mediated HIV-1 infection, the mechanisms of virological synapse 
formation must be fully elucidated.  Therefore, the involvement of HIV-1 Nef protein in 
VS formation was examined.  Nef interacts with a vast array of cellular factors, resulting 
in the alteration of many functions in HIV-infected cells; in the context of the HIV-1 VS, 
we were especially interested in those involving cell signaling via lipid rafts and actin 
dynamics, due to the importance of these pathways in VS formation.  We therefore 
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hypothesized that Nef could promote the formation of HIV-1 virological synapses.  Since 
virological synapse-mediated viral spread is the preferred mode of transmission in 
primary cells, we also hypothesized that any enhancement of the virological synapse by 
Nef may explain the increased replication kinetics observed in primary cells in the 
presence of Nef. 
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MATERIALS AND METHODS 
 
MATERIALS 
Media and supplements 
Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute 1640 
(RPMI-1640) medium, and Hank’s balanced salt solution (HBSS) were purchased from 
Lonza (Walkersville, MD).  Penicillin-streptomycin-glutamine and 0.25% trypsin were 
purchased from Gibco (Grand Island, NY).  Fetal bovine serum was purchased from 
Hyclone (Logan, UT).  Ampicilin sodium salt and kanamycin sulfate were purchased 
from United States Biological (Swampscott, MD).  The bacterial culture media described 
below were prepared in house, with materials purchased from Becton Dickenson (Sparks, 
MA).  Luria broth (LB) media contained 0.01 g/ml Bacto tryptone, 0.005 g/ml Bacto 
yeast extract, 0.005 g/ml NaCl, and 1 mM NaOH, with the addition of 15 g/L Bacto agar 
to make solid LB culture plates.  Super optimal broth with catabolite repression (SOC) 
contained 0.02 g/ml Bacto tryptone, 0.005 g/ml Bacto yeast extract, 0.5 g/ml NaCl, 10 
mM MgCl2, 10 mM MgSO4, and 20 mM glucose.  Working concentrations of antibiotics 
were 100 μg/ml ampicillin and 50 μg/ml kanamycin. 
 
Antibodies 
Mouse anti-JR-CSF Nef antibody (WB 1:1000, donated by Dr. K. Krohn and Dr. V. 
Ovod), Sim4 anti-CD4 antibody (IF 1:4, FC undil.), and p24 hybridoma supernatant (WB 
1:3) were obtained from the National Institute of Health (NIH) AIDS Reference Reagent 
Program.  W6/32 anti-MHC I hybridoma supernatant (FC undil.) was a gift from Dr. J. 
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Blum.  Mouse anti-PAK2 (WB 1:1000), rabbit anti-Myc (WB 1:2000), mouse anti-HA 
(WB 1:2000), goat anti-Nef 4D10 (WB 1:2000, FC 1:100, IF 1:50), mouse anti-ZAP70 
(WB 1:1000, IF 1:40), mouse anti-CD81 (WB 1:1000, IF 1:40), phycoerythrin (PE)-
conjugated rabbit anti-mouse (1:50), and fluorescein isothiocyanate (FITC)-conjugated 
rabbit anti-mouse (1:50) antibodies were obtained from Santa Cruz Biotechnologies Inc. 
(Santa Cruz, CA).  KC57 PE-conjugated anti-p24 (IF 1:80, FC 1:40) antibody was 
obtained from Coulter (Brea, CA).  PE- and horseradish peroxidase (HRP)-conjugated 
Cholera toxin subunit B (WB 1:5000), normal mouse IgG, and mouse anti-β-actin (WB 
1:2000) were from Sigma (St. Louis, MO).  Anti-mouse-HRP and anti-rabbit-HRP 
(1:3000) were obtained from GE Healthcare (Buckinghamshire, UK).  PE-conjugated 
phalloidin (IF 1:100), AlexaFluor 350 donkey anti-goat (1:50), AlexaFluor 488 donkey 
anti-goat (1:50), and AlexaFluor 488 goat anti-mouse (1:50) were from Invitrogen 
(Carlsbad, CA).  
 
Reagents 
ECL chemiluminesence reagents for Western blot detection were made in house.   
Poly(A)x(dT) and protease inhibitor cocktail set V were purchased from Roche 
(Indianapolis, IN).  N-acetyl T-20 was obtained from the National Institute of Health 
(NIH) AIDS Reference Reagent Program.  G418 sulfate and hygromycin were purchased 
from Calbiochem (LaJolla, CA).  The Lipofectamine 2000 system was purchased from 
Invitrogen (Carlsbad, CA).  T4 DNA ligase, calf intestinal phosphatase (CIP), and all 
restriction endonucleases were from New England Biolabs (Beverly, MA).  [Methyl-3H]-
thymidine 5’-triphosphate and [γ-32P] ATP were from PerkinElmer (Boston, MA).  Ficoll 
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was from Amersham Biosciences (Piscataway, NJ).  Phytohemagglutinin (PHA), 
interleukin-2 (IL-2), poly-L-lysine, cytochalasin D, piceatannol, methyl-β-cyclodextran, 
and 4’,6’-diamidino-2-phenylindol (DAPI) were purchased from Sigma (St. Louis, MO).  
All other chemicals were from Fisher (LaGrange, KY). 
 
Biotechnology systems 
The Expand High Fidelity PCR system was purchased from Roche (Indianapolis, IN).  
The QuickChange II Site-directed Mutagenesis kit and Strataclone PCR cloning kit were 
from Stratagene (Cedar Creek, TX).  The firefly luciferase assay system and the Wizard 
SV Gel and PCR Clean-up kit were from Promega.  The Bio-Rad DC Protein Assay kit 
was from Biorad Laboratories (Hercules, CA). 
 
METHODS 
Cells and cell cultures 
Cell lines 
Human embryonic kidney 293T cells, cervical carcinoma HeLa cells, and Jurkat 
lymphocytic cells were purchased from American Tissue Culture Collection (ATCC) 
(Manassas, VA).  U87.CD4.CXCR4 and U87.CD4.CCR5 cells (donated by Dr. D. 
Littman) were obtained from the National Institute of Health (NIH) AIDS Reference 
Reagent Program.  Stable cell lines were constructed by Dr. IW Park and have been 
previously described (Park and He 2009). 
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Competent cells for cloning 
GC5™ chemically competent E. coli were purchased from GeneChoice (Frederick, MD). 
 
Cell cultures 
293T, U87.CD4.CXCR4, U87.CD4.CCR5, and HeLa cells were cultured in DMEM 
supplemented with 10% fetal bovine serum, 100 µg/ml penicillin and streptomycin, and 2 
mM glutamine at 37˚C with 5% CO2.  Jurkat cells were cultured in RPMI supplemented 
with 10% fetal bovine serum, 100 µg/ml penicillin and streptomycin, and 2 mM 
glutamine at 37˚C with 5% CO2. 
 
Isolation and culture of peripheral blood mononuclear cells (PBMC) 
Peripheral blood (PB) was obtained from the Indiana Blood Center (Indianapolis, IN).  
PBMCs were isolated on a Ficoll-Plaque density gradient by centrifugation.  Briefly, 
buffy coats were diluted 1:2 in PBS and layered over 15 ml Ficoll in a 50 ml conical tube.  
The tubes were then centrifuged at 785 x g with no brake.  The white layer of PBMCs 
was extracted, and then washed in 40 ml PBS three times by centrifugation at 440 x g for 
5 min.  Cells were allowed to adhere to tissue culture dishes overnight, and non-adherent 
lymphocytes were collected.  PBMCs were seeded at a density of 2.5 x 106 cells/ml in 
RPMI supplemented with 10% fetal bovine serum, 100 µg/ml penicillin and 
streptomycin, and 2 mM glutamine, and stimulated with 3 μg/ml PHA for 48 hr followed 
by continued culture in RPMI containing 100 U/ml IL-2. 
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Plasmids 
Reporter viruses 
HIV-Luc plasmid was described elsewhere (He, Chen et al. 1997).  HIV-Luc.vif- was 
constructed by first subcloning an EcoR1/Spe1 fragment of HIV-Luc containing the vif 
gene into pBluescript vector, followed by site-directed mutagenesis to introduce a stop 
codon in vif using the primer pairs 5’-GTA AAA CAC CAT TAG TAT ATT TCA AGG 
AAA GC-3’ and 5’-GC TTT CCT TGA AAT ATA CTA ATG GTG TTT TAC-3’.  The 
mutated vif- portion was then placed back in HIV-Luc to create HIV-Luc.vif-. 
 
Nef mutants 
pNef.myc was constructed by first obtaining the nef gene from HIV-1 NL4-3 by PCR 
using the following primer pairs 5’-CCC AAG CTT ATG GGT GGC AAG TGG TCA-3’ 
and 5’-CCG GGA TTC TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA GCA 
GTT CTT GAA GTA CTC-3’.  The resulting PCR product was digested with 
EcoRI/BspEI restriction enzymes.  A YU2.nef plasmid was meanwhile digested with 
HindIII/BspEI and pcR3.1 with EcoRI/HindIII.  The resulting three fragments were 
isolated and ligated to result in an NL4-3nef construct.  nef point mutations 
(pNef153.myc, pNef177.myc, and Nef7.myc) were constructed in the context of 
pNef.Myc with primer pairs 5’-CCC AAG CTT ATG GGT GGC AAG TGG TCA-3’  
and 5’-CCG GAA TTC TCA AGA ACT TCA TGA GGC-3’; 5’-CCC AAG CTT CTT 
CTT CTC CGG TTA TTT CCT CTC TTG TGG-3’ and 5’-CCC AAG CTT TAG ACC 
GAG TTG ACC ATG ATC GAA CAT-3’; 5’-C CTG CAT GGA ATG GAT GAC CCG 
GGG AGA GAA GTG TTA GAG TGG AG-3’ and 5’-CT CCA CTC TAA CAC TTC 
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TCT CCC CGG GTC ATC CAT TCC ATG CAG G-3’, respectively.  For pNef.HA and 
pNef7.HA plasmids, the Myc tag in pNef.Myc and pNef7.Myc was replaced with primers 
5’-CCC TTA CCA TAT GAT GTT CCA GAT TAC GCT TGA AGC CGA ATT CTG 
CAG ATA-3’ and 5’-GG AAT TCC ATA TGG GTA CTC TGC GTT CTT GTA GTA 
CTC-3’.  pNef.GFP and pNef7.GFP plasmids were constructed in the context of the 
pEGFP.N3 backbone (Clontech, Mountain View, CA) using pNef.Myc and pNef7.Myc 
as respective templates and primers 5’-CCG GAA TTC ATG GGT GGC AAG TGG 
TCA-3’ and 5’-CCG ACT AGT GCA GTT CTT GAA GTA CTC-3’.  pNef7.A3G fusion 
vector was constructed by first mutating the stop codon of pNef.Myc with 
oligonucleotides 5’-CCG GAA TTC GTT CTT GTA GTA CTC CGG ATG-3’and 5’-
CAT CCG GAG TAC TAC AAG AAC GAA TTC CGG-3’ introducing an EcoR1 site, 
and then cloning the APOBEC3G ORF at the EcoRI site of Nef.  pNef7.A3G/D128K 
(D128K) and pNef7.A3G/E259Q (E259Q) plasmids were constructed in the context of 
pNef7.A3G with primer pairs 5’-CTC TAC TAC TTC TGG AAG CCA GAT TAC CAG 
GAG GCG-3’ and 5’-CGC CTC CTG GTA ATC TGG CTT CCA GAA GTA GTA 
GAG-3’; and 5’- GT TTC TTG AAG GCC GCC ATG CAC AGC TGT GCT TCC TG-
3’ and 5’-CA GGA AGC ACA GCT GTG CAT GGC GGC CTT CAA GAA AC-3’, 
respectively.   
 
HIV proviruses 
HIV.env-vif- plasmid has been previously described (Lewis, Hensel et al. 1992).  pNL4-3 
was obtained from NIH AIDS Reagent Program.  HIV.env-.nef- plasmid was generously 
provided by Dr. M. Emmerman.  HIVΔNef, HIV.nef-F191A, HIV.nef-AxxA, and 
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HIV.nef-62AAAA65 were constructed by first cloning an XhoI/NaeI NL4-3 Nef fragment 
into the pBlueScript KS+ vector, followed by site-directed mutagenesis using the 
Stratagene kit and the following primers.  F191A: 5’-TTT GAC AGC CGC CTA GCA 
GCT CAT CAC GTG G-3’ and 5’-CCA CGT GAT GAG CTG CTA GGC GGC TGT 
CAA A’3’; AxxA: 5’-TTT TCC AGT CAC AGC CCA GGT AGC TTT AAG ACC AAT 
GAC TTA CAA GG-3’ and 5’-CCT TGT AAG TCA TTG GTC TTA AAG CTA CCT 
GGG CTG TGA CTG GAA AA-3’; 62AAAA65: CTT GTG CCT GGC TAG AAG CAC 
AAG CGG CGG CAG CGG TGG GTT TTC CAG TC-3’ and 5’-GAC TGG AAA ACC 
CAC CGC TGC CGC CGC TTG TGC TTC TAG CCA GGC ACA AG-3’; nef-: 5’-TCT 
CGA GAC CTA TGA AAA CAT GGA GCA ATC ACA AG -3’ and 5’-CT  TGT GAT 
TGC TCC ATG TTT TCA TAG GTC TCG AGA-3’.  The mutated Nef fragments were 
then cloned back to pNL4-3 using XhoI/NaeI. 
Other plasmids 
pcDNA3.1-APOBEC3G-HA and psPAX2 plasmids were obtained from NIH AIDS 
Research Reagent Program and were donated by Dr. W. C. Greene and Dr. D. Trono, 
respectively.  pHLA-A2 plasmid was a kind gift from Dr. C. Toloukian.  VSV-G, 
HXB2.env, YU2.env, pc.CXCR4, and pc.CD4 plasmids were described elsewhere (He, 
Chen et al. 1997).   
 
 Bacterial transformation 
GC5™ cells were mixed with 0.5-1 μl DNA ligation reaction, and incubated on ice 30 
min.  The cells were heat-shocked at 42˚C for 45 sec, followed by incubation on ice 
another 2 min, and addition of 250 μl of RT SOC medium.  The cells were then incubated 
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at 37˚C for 1 hr with shaking of 240 RPM, and plated on LB plates containing the 
appropriate antibiotics. 
 
Cell transfections 
293T cells were transfected by the standard calcium phosphate precipitation method.  
HeLa cells were transfected using the Lipofectamine 2000 system (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s directions.  pcDNA3 was used throughout the 
studies to normalize the amounts of DNA for all transfections. 
 
Preparation of viruses and virus-like particles (VLP) 
Replication-competent HIV-1 and HIV viruses pseudotyped with different envelope 
proteins were prepared as previously described (He, Chen et al. 1997).  Briefly, 293T 
cells were transfected with proviral plasmids; HIV-Luc or HIV-luc.vif-; VSV-G, 
HXB2.env, or YU2.env; and Nef or each of Nef derivatives.  For inverse fusion VLP, 
293T cells were transfected with psPAX2 packaging vector (Dull, Zufferey et al. 1998), 
pc.CXCR4, pc.CD4, and Nef, Nef7, Nef7.A3G, or A3G.  Cell culture supernatants were 
collected 72 hr after transfection, filtered, and saved as progeny viruses.  Progeny viruses 
were then assayed for RT activity (He, Chen et al. 1997).  Briefly, filtered supernatant 
was centrifuged at 4˚C for 1 hr at 14,000 RPM to pellet the progeny virus.  The virus 
pellet was resuspended in 10 μl of dissociation buffer (0.25% Triton-X-100, 20% 
glycerol, 0.05 M Tris-HCl pH 7.5, 1 mM DTT, and 0.25 M KCl) and subjected to three 
freeze/thaw cycles.  RT assay buffer (0.083 M Tris-HCl pH 7.5, 0.008 M DTT, 0.0125 M 
MgCl2, and 0.083% Triton-X-100), 1 μl [3H]-dTTP, and 5 μl of 5 U/ml poly (A)x(dT) 
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was added to the dissociated virus and incubated at 37˚C for 1 hr.  The reaction was then 
spotted onto DE81 filters (Whatman, England), washed three times with 2X SSC (0.3 M 
NaCl, 0.03 M sodium citrate pH 7.0), and the radioactivity on the filter was determined in 
a Beckman LS6000IS scintillation counter.  Virus titer was expressed as cpm/ml, and 
normalized for the number of cells in cultures. 
 
Luciferase assays 
Firefly luciferase activity was measured using the luciferase assay system from Promega 
according to the manufacturer’s directions.  Briefly, cells were transduced with the 
appropriate amount of pseudotyped HIV-Luc virus at 37˚C for 2 hr then washed and 
cultured for an additional 48 hr in fresh medium.  In order to acquire approximately 
similar readings, the amount of VSV-G-pseudotyped viruses used was only one tenth that 
of YU2.env and HXB2.env-pesudotyped viruses.  Cells were washed with ice-cold PBS 
and counted, and equal numbers of cells were lysed in 1X firefly luciferase lysis buffer.  
Lysates were centrifuged briefly to pellet debris, 20 μl of supernatant was mixed with 
firefly luciferase substrate, and luciferase activity was determined using an Opticomp 
Luminometer (MGM Instruments, Hamden, CT).  
 
Virus replication assays 
VLP treatment 
VLP pseudotyped with CD4 and CXCR4 and containing Nef, Nef7, Nef7.A3G, or A3G 
were produced as described above.  Jurkat cells were transduced with replication-
competent HIV-1 HXB2 viruses of an RT activity of 10,000 cpm at 37˚C for 3 hr, and 
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washed to remove the remaining viruses.  Infected cells were then transduced twice with 
appropriate VLP; 50,000 cpm following HIV-1 infection and another 50,000 cpm the 
next day.  One third volume of cell culture supernatants was collected every other day 
and assayed for the RT activity, with fresh medium was added to the cultures to maintain 
culture volume.  The RT activity was determined as described and normalized to the cell 
counts. 
 
Virological synapse replication kinetics 
Jurkat cells were infected with replication-competent WT HIV or HIVΔNef and allowed 
to reach close to 100% infection as determined by intracellular p24 staining.  Infected 
cells were then mixed with uninfected cells in a 1:3 ratio, with 1 x 106 cells/ml in 24-well 
tissue culture plates.  Infections were cultured with or without 100 μg/ml T-20 and 
monitored for the RT activity daily as described. 
 
Immunoblotting 
Whole cell lysates 
Cells were washed twice with ice-cold PBS.  Cells were collected and lysed in RIPA 
buffer (10 mM NaHPO4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium 
deoxycholate, 0.2% sodium azide, 0.004% sodium fluoride, 1 mM sodium orthovanadate 
in PBS) and 1x protease inhibitor cocktail for 30 min on ice, and cell lysates were 
obtained by centrifugation to remove cell debris.  Protein concentration was determined 
using a Bio-Rad DC protein assay kit.  Equal amounts of protein were separated by 8-
12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and 
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transferred to Hybond ECL membranes (Amersham).  The membranes were blocked for 
1 hr in 5% milk or 3% BSA in TBST buffer, and then probed with specific primary 
antibodies and appropriate HRP-conjugated secondary antibodies.  Chemiluminesence 
visualization was performed using a homemade ECL system.  Relative levels of protein 
were determined by densitometric scanning of the blots and normalized using appropriate 
loading controls. 
 
Membrane and cytosolic fractionation 
Cells were washed twice with ice-cold PBS, then lysed in hypotonic buffer (10 mM Tris-
HCl pH 8.0, 1.5 mM MgCl2, 10 mM KCl, protease inhibitors) for 20 min on ice.  Cells 
were homogenized by passing through a 27-gauge needle 20 times, and then pelleted at 
1500 x g for 10 min to pellet nuclei.  The supernatant was then centrifuged at 14,000 rpm 
for an additional 45 min.  This supernatant was saved as the cytosolic fraction, while the 
pellet was resuspended in RIPA buffer and saved as the membrane fraction. 
 
Viruses 
Viruses with an equal level of RT activity were pelleted by centrifugation at 14,000 RPM 
for 1 hr, then lysed in RIPA buffer and separated on a 12% SDS-PAGE gel.  Relative 
levels of protein incorporation into virions were determined by densitometric scanning of 
the blots and calculated using HIV-1 p24 as an internal standard. 
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Immunoprecipitation and in vitro kinase assays (IVKA) 
For immunoprecipitation/Western blot analysis, cells were lysed in whole cell extraction 
buffer (WEB) (50 mM Tris-HCl pH8.0, 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 2 
mM EGTA, 10% glycerol, 1X protease inhibitor, 1mM sodium orthovanadate, 160 mM 
NaF, 10 mM pyrophosphate).  Lysates containing equal amounts of protein were pre-
clared by incubation at 4˚C for 30 min with ProteinA-agarose beads.  Pre-cleared lysates 
were then incubated with appropriate antibodies, using normal mouse or rabbit IgG as a 
control, at 4˚C for 16 hr with constant rocking.  ProteinA-agarose beads were added, and 
incubated for an additional 2 hr.  Beads were pelleted and washed twice with IP washing 
buffer (50 mM Tris-HCl pH 7.5, 120 mM NaCl, 0.25% NP-40, 4 mM NaF, 1 mM sodium 
orthovanadate, 0.2 mM EDTA, 0.2 mM EGTA, 10% glycerol) and resuspended in 25 μl 
SDS-PAGE loading buffer, followed by SDS-PAGE and Western blotting as described.  
For in vitro kinase assays, the immunoprecipitates were suspended in 30 µl kinase assay 
buffer (50 mM HEPES pH 8.0, 150 mM NaCl, 5 mM EDTA, 10 mM MgCl2, 0.02% 
Triton X-100) and 10 µCi [-32P]-ATP (3000 Ci/mmol) was added to the reaction.  After 
incubation at room temperature for 5 min, the reaction was separated by SDS-PAGE and 
the gel was dried for 2 hr using a vacuum gel drier (Pharacia Biotech) and exposed to X-
ray film. 
 
Raft floatation assays 
Transfected 293T cells or stable GFP- and Nef-GFP-expressing Jurkat cells were cultured 
at the same density for 48 hr, with some samples being treated with 8 mM methyl-β-
cyclodextran for 1 hr before harvesting.  Cells were then incubated on ice for 30 min, 
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washed, and lysed in lipid raft lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 
mM EDTA, 1% Triton-X-100, and 1X protease inhibitors) on ice for 60 min.  Lysates 
were adjusted to 40% sucrose, and loaded into 5.2 ml ultracentrifuge tubes, then carefully 
layered with 2.2 ml 30% sucrose in PBS and 2.2 ml 5% sucrose in PBS.  The gradients 
were then centrifuged at 200,000 x g, 4˚C for 18 hr with no brake.  Ten 0.5 ml aliquots 
were taken from the top and applied to  Hybond ECL membranes via a slot blot manifold 
(Schleicher and Schuell, Keene, NH), then analyzed using the appropriate antibodies as 
described. 
 
Oil Red O (ORO) staining 
Oil Red O stock solution was made by dissolving 0.5 g powder in 100 ml isopropanol.  
ORO stock solution was diluted 3:2 in dH2O and incubated at RT for 10 min, then 
filtered to remove precipitates.  Diluted ORO was added to cells and stained for 15 min at 
RT, then cells were rinsed three times with 60% isopropanol and once with PBS. 
 
Immunofluoresence staining 
Stable cell lines 
Coverslips were coated with 0.1% poly-L-lysine for 5 min, then washed and dried for at 
least 2 hr.  Stable GFP- or Nef mutant-GFP expressing Jurkat cells were seeded onto 
coated coverslips at a density of 1 x 106 in 200 μl RPMI, and incubated at 37˚C for 1.5 hr.  
The cells were then fixed in 4% paraformaldehyde (PFA) at RT for 15 min, 
permeabilized in 0.1% Triton-X-100 at 4˚C for 20 min and blocked in 5% FBS/1% BSA 
for 30 min.  Cells were then stained for CD81 with anti-mouse-PE secondary antibody, 
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CD3 with anti-mouse PE secondary antibody, GM1-PE, or F-actin (phalloidin-PE), with 
extensive washing with HBSS between each step.  A set of cells stained for GM1 were 
treated with 8 mM methyl-β-cyclodextran for 1 hr before fixation as a negative control, 
and a set of cells stained for F-actin were treated with 30 μg/ml piceatannol for 2 hr prior 
to staining.  Approximately 100-150 cells were examined for each condition. 
 
Virological synapse formation and Nef transfer 
For quantification of VS formation, uninfected target Jurkat cells were stained with 2.5 
μM CFSE at 37˚C for 10 min then mixed with infected cells in a 1:1 ratio and loaded 
onto poly-L-lysine-coated coverslips at a density of 1 x 106 cells in 200 μl RPMI.  
Synapses were allowed to form for 1.5 hr, and then cells were fixed, permeablized, and 
stained as described above using p24-PE, CD4 with anti-mouse-PE secondary antibody, 
gp120 with anti-goat Alexa 350, ZAP70 with anti-mouse-FITC, or pTyr with anti-mouse-
FITC.  For Nef transfer staining, cells were fixed and permeablized as described and 
stained for Nef, then stained with 10 μM DAPI at RT for 25 min.  Confocal microscopy 
analysis was carried out on a Zeiss LM510, with red and green fluorescence acquired 
sequentially.  Images were further processed to adjust brightness and contrast in 
Microsoft PowerPoint. 
 
Flow cytometry analysis 
MHC I and CD4 downregulation 
Transfected HeLa cells were washed with cold PBS and detached from the tissue culture 
plate using 0.5 mM EDTA in PBS.  Cells were then suspended in Sim4 (CD4) or W6/32 
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(MHC I) supernatant and incubated at 4˚C for 1 hr, then PE-conjugated rabbit anti-mouse 
IgG for an additional 1 hr in the dark.  Cells were washed three times with cold HBSS 
(1x Hank’s Salt solution, 4 mM NaCHO3, 1% BSA and 0.02% NaN3) between all steps.  
The cells were then fixed in 1% paraformaldehyde at 4˚C for 4 hr, then washed with PBS 
and analyzed for MHC I or CD4 expression using a FACScalibur II (Becton Dickinson) 
with CellQuest software.   
 
Analysis of Nef-GFP intracellular delivery     
To determine delivery of virion-incorporated Nef-GFP fusion proteins, VSV-G-
pseudotyped HIV.env-.nef- virions containing Nef-GFP or Nef7-GFP were prepared as 
described above.  The viruses were used to infect 293T cells via spinoculation as 
described (Peretti, Schiavoni et al. 2005).  Briefly, 50,000 cpm of virus was allowed to 
adsorb onto cells by centrifugation at 150 x g at room temperature for 1 hr, followed by 
incubation at 37˚C for 3 hr.  Cells were then trypsinized and washed to remove cell 
surface-bound viruses and fixed, then analyzed for GFP-positive cells using a 
FACScalibur II. 
 
GM1/CD81 polarization 
Polarization of GFP- or Nef-transfected 293T cells was determined with or without 
treatment with 1 μM cytochalasin D for 1 hr and removed from the tissue culture plate 
using 0.5 mM EDTA in PBS.  Polarization of stable Jurkat cell lines was determined with 
or without overnight treatment with 1 μM cytochalasin D or 30 μg/ml piceatannol.  Cells 
were fixed and stained for GM1 or CD81 as described above, and analyzed for surface 
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intensity as a measurement of polarization using a FACScalibur II.  For negative controls 
of GM1 distribution, cells were treated with 8 mM methyl-β-cyclodextran for 1 hr prior 
to harvesting. 
 
Gag transfer 
For Gag transfer analysis CFSE-labeled target Jurkat cells were incubated with infected 
cells in a 1:1 ratio in 96-well tissue culture plates, at a density of 1 x 106 cells per 200 μl 
RPMI.  All samples contained 100 μg/ml T-20, and 1 μM cytochalasin D or 30 μg/ml 
piceatannol were added to select samples.  At the indicated timepoints cells were fixed, 
permeablized, and stained for p24 as described above.  Flow cytometry samples were 
analyzed for the percent of Gag+ target cells using a FacsCaliburII. 
 
Data acquisition and statistical analysis 
All values are expressed as mean  s.d.  All comparisons were made using two-tailed 
Student’s t-test.  A p value of < 0.05 was considered statistically significant (*), and p < 
0.01 highly significant (**). 
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RESULTS 
 
PART 1: NOVEL ANTI-HIV THERAPIES USING A NEF-MUTANT FUSION 
PROTEIN  
1.1 Comparison of Nef and Nef7 mutants 
The properties of Nef7 render it uniquely suitable as a carrier platform for therapeutic 
proteins.  Our strategy involved packaging of Nef7-fusion proteins into virus-like 
particles (VLP) that could then be targeted to HIV-infected cells through a process 
known as inverse fusion (Endres, Jaffer et al. 1997), wherein CD4 and CXCR4/CCR5 
pseudotyped VLP bind to gp120 on the infected cell surface and allow delivery of VLP 
contents into the infected cell.  We therefore constructed four Nef constructs: WT Nef, 
Nef V157L, Nef E177G, and Nef7, that contains both point mutations and analyzed them 
for their effects on the host cell.  First, we transfected 293T cells with each of the Nef 
plasmids or the empty cDNA3 vector as a control and determined the cytosolic and 
membrane expression of each (Fig. 8A).  Nef7 had been previously shown to localize to 
lipid rafts to a greater extent than WT Nef, but it was not shown whether this was due to 
an overall increase of Nef7 to the membrane or a more specific targeting of Nef7 to lipid 
rafts.  Our data shows that while Nef7 does have a slight increase in membrane 
localization as compared to WT Nef, this is not a large difference and thus the increased 
lipid raft localization of Nef7 is likely not due to a general increase in membrane 
localization.  Importantly, all four Nef constructs showed a similar level of overall 
cellular expression, indicating that they were stable (Fig. 8B).  Next, we transfected 293T 
cells with HIV.env-.nef-, an HIV non-replication-competent provirus that is defective 
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Figure 8.  Cytosolic and membrane expression of Myc-tagged Nef and Nef mutants.  
293T cells were transfected with WT Nef or each of the Nef mutants.  Cells were 
harvested 72 hr post-transfection either as whole cell lysate or separated into cytosolic 
and membrane fractions, then separated by 12% SDS-PAGE.  A.  The ratio of cytosolic 
(C) to membrane (M) localization of Nef was determined by Western blot analysis using 
an anti-myc antibody, with membrane expression normalized to calnexin and cytosolic 
expression normalized to actin.  B.  Whole cell lysate was subjected to Western blot 
analysis using an anti-Myc antibody with antibodies against β-actin as a loading control.  
Data were representative of 3 independent experiments. 
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for Nef expression, in combination with each of the four Nef plasmids.  We examined the 
virus production from transfected cells as well as the cytotoxicity of each of the Nef 
mutants and found that there was no significant difference in virus production (Fig. 9A) 
or cell death (Fig. 9B) among cells expressing these Nef proteins.  Therefore, we 
concluded that at least in terms of its effect on the expressing cell, Nef7 had no properties 
that would disqualify it from being used as a protein carrier in our system. 
 
1.2 Enhanced virion incorporation of Nef7 as compared to WT Nef 
To test our hypothesis that A3G fusion to Nef7 (Nef7.3AG) can restore the virion 
incorporation of A3G and inactivate HIV-1 infectivity in the presence of HIV-1 Vif 
expression, we first ascertained the high virion incorporation property of Nef7.  We 
utilized the constructed Nef and Nef7 mutants, in which V152L and E177G point mutations 
were introduced, to compare their ability to be incorporated into HIV-1 virions.  We first 
transfected 293T cells with HIV.env-.nef- in combination with WT Nef or Nef 7.  We also 
transfected plasmids containing each of the two single point Nef7 mutants V152L and 
E177G in these experiments.  Viruses were collected 72 hr post transfection and assayed 
for RT activity.  Next, supernatants containing equal levels of RT activity were 
centrifuged and the pellets lysed in RIPA buffer, then subjected to Western blot analysis 
using an antibody against a Myc epitope that was engineered to the C terminus of all Nef 
recombinant proteins and an anti-HIV p24 antibody that detected the HIV-1 capsid 
protein (Fig. 10A).  The p24 levels detected by Western blot sometimes varied among 
samples, but as this was not consistently the case it is likely due to inconsistent pelleting 
of virus or accidental removal of a portion of the virus pellet when removing the 
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Figure 9.  Virus production and cytoxicity in Nef7-expressing cells.  A.  293T cells 
were transfected with HIV.env-.nef- together with each of the Nef plasmids.  Seventy-two 
hours post-transfection, cell supernatants were collected and virus production was 
determined as measured by reverse transcriptase activity, normalized to cell number.  B.  
Transfected 293T cells were analyzed at 72 hr post-transfection for viability, with the 
number of live cells determined by trypan blue exclusion.  Data were representative of 2 
independent experiments. 
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Figure 10.  Virion incorporation of Nef7.  A.  293T cells were transfected with 
HIV.env-.nef- and WT Nef, NefV153L, NefE177G, or Nef7 with pcDNA3 included as a 
control.  Progeny viruses were collected 72 hr post transfection and quantified for their 
RT activity.  Viruses with an equal level of RT activity were pelleted and analyzed for 
Western blot analysis using an antibody against the Myc epitope that was added to the C 
terminus of all Nefs and an antibody against HIV-1 p24 antigen.  B.  The relative (rel.) 
level of virion protein from three independent experiments was determined by 
densitometry and normalized to the virion p24 level.  The WT Nef value was set as 1. *: 
p<0.05 as compared to WT Nef.  Data was mean ± s.d. 
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supernatant.  Relative virion Nef incorporation was normalized to HIV-1 p24.  We found 
that compared to WT Nef, Nef7 showed approximately 9-fold higher virion incorporation 
(Fig. 10B).  There was little virion incorporation of WT Nef, V153L, and E177G over the 
cDNA background control.  These results confirm that Nef7 is capable of being 
incorporated into HIV-1 virions at a higher level than WT Nef, and also show that both 
point mutations are required for increased virion incorporation.   
 
1.3 Efficient delivery of virion Nef7 into target cells  
We next determined whether virion incorporated Nef would be efficiently delivered into 
target cells.  We constructed Nef-GFP and Nef7-GFP fusion plasmids and transfected 
them into 293T cells along with HIV.env-.nef- and vesicular stomatitis virus envelope 
(VSV-G) to produce GFP-labeled VSV-G-pseudotyped HIV-1 particles.  GFP expression 
in trans and incorporation into HIV-1 virions would allow accurate quantitation of the 
delivery efficiency of virion proteins into host cells.  Thus, we infected fresh 293T cells 
with these newly pseudotyped viruses containing an equal level of RT activity by 
spinoculation and analyzed the percentage of GFP+ cells in each infection (Fig. 11A).  In 
agreement with the virion incorporation, about 5-6 fold more GFP+ cells were detected in 
the infections by viruses carrying Nef7-GFP than those of viruses carrying WT Nef-GFP 
(Fig. 11B), suggesting that virion Nef7 protein can be efficiently delivered into target 
cells through infection.   
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Figure 11.  Delivery of virion WT Nef and Nef7 into cells.  A.  293T cells were 
transfected with HIV.env-.nef- and VSV-G, and WT Nef-GFP or Nef7-GFP expression 
plasmids.  Progeny viruses were collected and quantitated as stated above.  Viruses with 
an equal level of RT activity were used to infect fresh 293T by spinoculation.  Uninfected 
cells (uninf.) were used as a control.  After 3 hr cells were washed to remove unbound 
viruses and then trypsinized to remove cell surface-bound virus.  These cells were then 
analyzed for GFP-positive cells by FACS to detect intracellular delivery of virion Nef.  
B.  The relative level of GFP-positive cells from three independent experiments was 
calculated with the number of GFP-positive cells in WT Nef-GFP infection set to 1.  
*: p<0.05 as compared to uninfected cells.  Data was mean ± s.d. 
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1.4 Higher virion incorporation of the Nef7.A3G fusion protein   
Next, we determined whether Nef7 in the form of fusion with A3G (Nef7.A3G) retained 
the higher virion incorporation property of Nef7.  We therefore constructed the 
Nef7.A3G fusion expression plasmid, wherein the A3G without its start codon was 
cloned to the 3’ end of the Nef7 gene before the termination signal.  Since the A3G 
fusion construct contained an HA epitope tag and the Nef constructs all contained a Myc 
epitope tag, we also replaced the Myc tag on the Nef constructs with an HA tag in order 
to facilitate the comparison of expression levels of each of these constructs.  We 
confirmed that the new HA tag was working and that all proteins were stably expressed 
by transfecting 293T cells with WT Nef, Nef7, Nef7.A3G, or A3G (Fig. 12).  We then 
prepared HIV.env-.nef- viruses carrying WT Nef, Nef7, Nef7.A3G, or A3G, as described 
above and compared Nef7 and Nef7.A3G for their virion incorporation by Western blot 
analysis (Fig. 13A).  We also included WT Nef and A3G as controls in these 
experiments.  Quantitation of virion protein incorporation showed that Nef7 and 
Nef7.A3G had comparable levels in HIV-1 virions (Fig. 13B).  As Nef is a virion protein, 
it was detected in the virus blot.  On the other hand, Vif expression greatly diminishes 
encapsidation of A3G in the virus particles and as a result, only a very faint band of A3G 
appeared in the virus blot.  These results indicate that Nef7.A3G fusion does not alter the 
higher incorporation of Nef7 into HIV-1 virions. 
 
1.5 No PAK2 activation by the Nef7.A3G fusion protein   
In order to utilize Nef7 as a therapeutic carrier molecule, it must not be inherently toxic.  
Previous work has shown that, while WT Nef is extremely pathogenic, Nef7 is defective 
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Figure 12.  Expression of HA-tagged Nef, Nef7, A3G, and Nef7.A3G genes.  293T 
cells were transfected with WT Nef, Nef7, Nef7.A3G, or A3G expression plasmids with 
pcDNA3 included as a control.  Whole cell lysate was subjected to Western blot analysis 
using an antibody against an HA epitope that was added to the C terminus of all Nefs, 
Nef7.A3G and A3G and antibodies against β-actin as a loading control.  Data were 
representative of 3 independent experiments. 
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Figure 13.  Virion incorporation of Nef7.A3G.  A.  293T cells were transfected with 
HIV.env-.nef- and WT Nef, Nef7, Nef7.A3G, or A3G expression plasmids with pcDNA3 
included as a control.  Progeny viruses were collected and subjected to Western blot 
analysis using an anti-HA antibody, with antibodies against HIV-1 p24 as a loading 
control.  B.  Virion protein levels were quantified from three independent experiments, as 
described above.  *: p<0.05.  Data was mean ± s.d. 
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for a number of key Nef activities and is therefore much less toxic than WT Nef.  
Activation of p21-activated kinase-2 (PAK2) is an important mechanism whereby Nef 
exerts its pathogenic function on the host (Sawai, Khan et al. 1996).  Nef7 does not 
activate PAK2 (D'Aloja, Santarcangelo et al. 2001).  Therefore, we determined whether 
the Nef7.A3G fusion led to PAK2 reactivation.  We transfected 293T cells with HIV.env-
.nef- and WT Nef, Nef7, or Nef7.A3G.  We first performed Western blot analysis for 
endogenous PAK2 expression in all transfections using an anti-PAK2 antibody.  We also 
performed Western blot analysis using an anti-HA antibody to ensure a comparable level 
of Nef expression, using an anti--actin antibody to ensure equal loading of the cell 
lysates.  As expected, there was little change in endogenous PAK2 level among all 
transfections (Fig. 14A).  We then performed immunoprecipitation of the cell lysates 
using an anti-HA antibody, followed by an in vitro kinase assay for PAK2 
phosphorylation.  PAK2 phosphorylation, an indicator of PAK2 activation, was only 
detected in cells that were transfected with WT Nef (Fig. 14B).  There was no 
phosphorylation signal in cells that were transfected with Nef7, Nef7.A3G, or the 
pcDNA3 control.  To ascertain whether the inability of Nef7 and Nef7.A3G to inactivate 
PAK2 was due to altered association between PAK2 and these Nef derivatives or an 
inability of associated Nef to activate PAK2, we performed immunoblotting of the 
immunoprecipitates using an anti-PAK2 antibody.  Compared to the pcDNA3 control, 
Nef7 and Nef7.A3G exhibited a similar level of immunoprecipitated PAK2 to that of WT 
Nef (Fig. 14C).  Taken together, these results show that like Nef7, Nef7.A3G does not 
activate PAK2 and that the failure of these two Nef derivatives to activate PAK2 is not 
due to changes in the level of endogenous PAK2 expression by these Nefs or to changes 
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Figure 14.  Effects of Nef, Nef7 and Nef7.A3G on PAK2 activation.  A.  293T cells 
were transfected with HIV.env-.nef- and WT Nef, Nef7, or Nef7.A3G expression 
plasmids with pcDNA3 included as a control.  Cells were harvested for whole cell lysates 
72 hr after transfection for Western blot analysis against anti-HA and anti-PAK2, with -
actin used to ensure comparable loading of cell lysates.  B.  Cell lysates were also 
subjected to immunoprecipitation with anti-HA antibodies, followed by an in vitro kinase 
assay using -32P-ATP to detect PAK2 activation.  C.  Cell lysates were first 
immunoprecipitated with anti-Nef antibody and then Western blotted with anti-PAK2 
antibody.  Data were representative of 3 independent experiments. 
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in the binding affinity of these Nefs to PAK2 but instead due to an inability of Nef7 to 
induce autophosphorylation of PAK2.         
 
1.6 Downregulation of CD4 and MHC I by Nef7.A3G   
Another key function of Nef is the downregulation of cell surface expression of various 
membrane proteins, the most well-known being CD4 and MHC I (Roeth and Collins 
2006).  Nef7 is reported to be defective in both CD4 and MHC I downregulation 
(D'Aloja, Santarcangelo et al. 2001).  We therefore attempted to confirm the diminished 
pathogenic phenotype of Nef7 and to determine whether this activity was present in the 
Nef7.A3G fusion protein by taking advantage of a system that was previously validated 
to study Nef-mediated MHC I downregulation (Lubben, Sahlender et al. 2007).  We 
adapted this system to determine the relationship between cell surface expression of CD4 
and MHC I and expression of Nef or its derivatives.  We transfected HeLa cells with 
plasmids expressing CD4, GFP and each of the Nefs using Lipofectamine.  After 24 hr 
we performed cell surface immunofluorescence staining using an anti-CD antibody and a 
phycoerythrin (PE)-conjugated secondary antibody followed by flow cytometry analysis.  
We first gated for GFP+ cells, and then examined the levels of CD4 expression among all 
GFP+ cells (Fig. 15).  We also performed similar experiments with MHC I (Fig. 16).  As 
expected, WT Nef downregulated both CD4 and MHC I expression.  In contrast, Nef7 
and Nef7.A3G showed no significant changes in the surface expression of these two 
receptors.  These results show that neither Nef7 nor Nef7.A3G alter the cell surface 
expression of CD4 and MHC I. 
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Figure 15.  Effects of Nef, Nef7 and Nef7.A3G on cell surface expression of CD4.  A.  
HeLa cells were transfected with CD4, GFP, and Nef, Nef7, or Nef7.A3G expression 
plasmids with pcDNA3 included as a control.  At 24 hr post-transfection cells were 
harvested and stained with an anti-CD4 antibody, followed by a PE-conjugated secondary 
antibody.  The cells were then gated for the GFP+ cells by FACS and only the GFP+ cells 
were analyzed for cell surface CD4 expression.  The M1 gate was determined by staining 
with mouse IgG followed by anti-mouse-PE.  B.  The relative CD4 levels from three 
independent experiments were calculated with the CD4 level in pcDNA3-transfected 
cells set to 100%.  *: p<0.05.  Data was mean ± s.d. 
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Figure 16.  Effects of Nef, Nef7 and Nef7.A3G on cell surface expression of MHC I.  
A.  HeLa cells were transfected with GFP, and Nef, Nef7, or Nef7.A3G expression 
plasmids with pcDNA3 included as a control.  At 24 hr post-transfection cells were 
harvested and stained with an anti-MHC I antibody, followed by a PE-conjugated 
secondary antibody.  The cells were then gated for the GFP+ cells by FACS and only the 
GFP+ cells were analyzed for cell surface MHC I expression.  The M1 gate was 
determined by staining with mouse IgG followed by anti-mouse-PE.  B.  The relative 
MHC I levels from three independent experiments were calculated with the MHC I level 
in pcDNA3-transfected cells set to 100%.  **: p<0.01.  Data was mean ± s.d. 
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1.7 Impaired HIV-1 infectivity in 293T cells by Nef7.A3G virion incorporation  
Nef7.A3G was detected in HIV-1 virions in the context of HIV-1 Vif expression (Fig. 
13).  It did not activate PAK2 (Fig. 14) or downregulate CD4 and MHC I expression 
(Fig. 15, 16).  Since we had determined that the Nef7.A3G fusion protein retained the 
characteristics of Nef7 and could therefore be utilized in our therapeutic strategy, we next  
determined whether it also retained the characteristics of A3G in the context of the fusion 
protein.  Therefore we determined the effect of Nef7.A3G on the HIV-1 infectivity.  We 
transfected 293T cells with HIV-Luc or HIV∆vif, VSV-G and Nef or each of the Nef 
derivatives to produce VSV-G-pseudotyped HIV-Luc viruses carrying each of the Nefs.  
HIV∆vif has no functional env or vif gene, while HIV-Luc contains no functional HIV-1 
env or nef gene and has the Luc reporter gene inserted at the 5’ end of the nonfunctional 
nef gene; it allows in trans complementation of other viral envelopes to determine the 
viral tropism and only single round infection for accurate determination of HIV-1 entry 
(He, Chen et al. 1997).  VSV-G envelope was used to facilitate HIV-1 infection of cells 
that do not usually express HIV-1 receptor CD4 and chemokine receptors CXCR4 or 
CCR5.  To ensure the specificity of Nef7.A3G, we also constructed and included two 
Nef7.A3G point mutants as controls: Nef7.A3G/D128K (D128K) and Nef7.A3G/E259Q 
(E259Q) in these experiments.  Both point mutations were made in the A3G portion of 
the fusion protein.  D128K mutation does not bind to HIV-1 Vif protein and renders the 
A3G protein Vif-resistant (Huthoff and Malim 2007; Zhang, Saadatmand et al. 2008), 
while E259Q mutation within the second deaminase domain leads to enzymatically 
inactive A3G (Schumacher, Hache et al. 2008).  In addition, we also included A3G alone 
in the transfection as a control. 
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We collected viruses from transfected cells, harvested these transfected cells for cell 
lysates, and performed Western blot analysis using an anti-HA antibody on the cell lysate 
and virus of both the HIV-Luc (Fig. 17A) and HIV∆vif (Fig. 17B) transfections.  As 
expected, due to differential sensitivity to Vif-mediated degradation, A3G had the lowest 
level in the cells, while Nef7.A3G(D128K) had the highest level in the cells.  The 
expression levels of both Nef7.A3G and Nef7.A3G(E259Q) were found to be between 
A3G and Nef7.A3G(D128K), suggesting that Nef fusion had made A3G less sensitive to 
Vif-mediated degradation.  As a result, Nef7.A3G(D128K) was incorporated slightly 
more into viruses than Nef7, Nef7.A3G, or Nef7.A3G(E259Q).  Compared to the above 
findings, lack of Vif expression (and therefore Vif-mediated degradation) resulted in a 
similar level of detection of A3G and the three A3G fusion proteins in both the cells and 
the viruses.  On the other hand, lack of Vif expression did not alter the fact that Nef7 was 
always detected in virions much more than its wild-type counterpart Nef.  Taken 
together, these results indicate that Nef7.A3G is partially Vif-resistant but not to the same 
extent as Nef7.A3G(D128K), possibly due to structural constraints on the binding of Vif 
to the fusion protein.  However, the extent to which the levels of Nef7.A3G and 
Nef7.A3G(D128K) differ between cells and viruses suggests that the slight resistance of 
Nef7.A3G to Vif  is not solely responsible for its higher virion incorporation.   
 
In parallel, we used virus collected from the HIV-Luc transfections to infect fresh 293T 
cells.  As expected, viruses carrying WT Nef and Nef7 and HIV-Luc viruses collected 
from A3G-transfected cells showed a level of infectivity similar to that of pcDNA3 
control viruses, as measured by the Luc activity (Fig. 18).  Compared to viruses carrying 
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Figure 17.  Expression and virion incorporation of Nef7.A3G and its derivatives.  A.  
293T cells were transfected with HIV-Luc and VSV-G, and WT Nef, Nef7, Nef7.A3G, 
Nef7.A3G(D128K), Nef7.A3G(E259Q), or A3G with pcDNA3 included as a control.  At 
72 hr post-transfection progeny viruses were collected and quantitated for RT activity.  
Whole cell lysates and progeny viruses were analyzed by Western blot using an anti-HA 
antibody, with a -actin or p24 Western blot analysis to ensure comparable gel loading.  
B.  293T cells were transfected with HIV-Luc.vif- and VSV-G, and WT Nef, Nef7, 
Nef7.A3G, Nef7.A3G(D128K), Nef7.A3G(E259Q), or A3G with pcDNA3 included as a 
control.  At 72 hr post-transfection whole cell lysates and progeny viruses were analyzed 
for HA expression as described above.  Data were representative of two independent 
experiments.
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Figure 18.  Effects of virion incorporation of Nef and its derivatives on the 
infectivity of VSG-pseudotyped HIV-Luc reporter viruses.  293T cells were 
transfected with HIV-Luc or HIV-Luc.vif-, VSV-G, and WT Nef, Nef7, Nef7.A3G, 
Nef7.A3G(D128K), Nef7.A3G(E259Q), or A3G with pcDNA3 included as a control.  At 
72 hr post-transfection progeny viruses were collected and quantitated for RT activity.  
HIV-Luc or HIV-Luc.vif- progeny viruses with an equal level of RT activity were then 
used to infect fresh 293T cells.  Infected cells were harvested 48 hr post-infection and 
analyzed for luciferase activity.  *: p<0.05, **: p<0.01.  Data were mean ± s.d. and 
representative of 4 independent experiments. 
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WT Nef or Nef7, HIV-Luc viruses carrying Nef7.A3G showed a marked decrease in 
infectivity.  Moreover, the infectivity of the viruses carrying the Vif-resistant D128K 
mutant was further decreased over that of its counterpart Nef7.A3G, while the viruses 
carrying the nonfunctional A3G mutant E259Q showed little inhibition.  To ensure the 
functionality of all the A3G derivatives and the non-functionality of the E259Q mutant, 
we constructed HIV-Luc.vif-, which contains a stop codon at the beginning of the vif 
gene, rendering it nonfunctional, and included it as a control in the infectivity 
experiments.  The HIV-Luc.vif- viruses containing Nef7.A3G, Nef7.A3G(D128K) and 
A3G showed complete inhibition of infection, similar to that observed in the HIV-Luc 
viruses containing the Vif- resistant  Nef7.A3G(D128K) mutant.  On the other hand, the 
inactive Nef7.A3G(E259Q) mutant had little effect on infectivity, regardless of Vif 
expression.  These results show that although Nef7.A3G virion incorporation does not 
restrict HIV-1 infection to the same extent as A3G does in the absence of Vif as 
demonstrated by the Nef7.A3G(D128K) mutation, it does significantly impair HIV-1 
infectivity, even in the presence of Vif.   
 
1.8 Impaired HIV-1 infectivity in U87 cells by Nef7.A3G virion incorporation  
To further corroborate these findings and to ensure that Nef7.A3G also inhibited 
infectivity of HIV virions that enter the cell by utilizing the HIV-1 receptors instead of 
the pH-dependent VSV-G fusion, we prepared HXB2.env- and YU2.env-pseudotyped 
HIV-Luc viruses carrying WT Nef, Nef7, Nef7.A3G or A3G.  We used HXB2.env 
pseudotyped viruses to infect U87.CD4.CXCR4 cells (Fig. 19A) or YU2.env- 
pseudotyped viruses to infect U87.CD4.CCR5 cells (Fig. 19B), and determined the 
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Figure 19.  Effects of virion incorporation of Nef and its derivatives on the 
infectivity of HXB2.env- and YU2.env-pseudotyped HIV-Luc reporter viruses.  A.  
293T cells were transfected with HIV-Luc, HXB2.env, and WT Nef, Nef7, Nef7.A3G, or 
A3G expression plasmids with pcDNA3 included as a control.  At 72 hr post-transfection 
the viruses were collected and quantitated for RT activity.  Viruses with an equal level of 
RT activity were used to infect U87.CD4.CXCR4 cells, and the infected cells were 
harvested for the Luc activity assay 48 hr post infection.  B.  Similarly, various YU2.env-
pseudotyped HIV-Luc viruses carrying Nef and each of its derivatives were prepared and 
used to infect U87.CD4.CCR5 cells.  *: p<0.05.  Data were mean ± s.d. and 
representative of 3 independent experiments.
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infectivity.  Similar to the results obtained using VSV-G-pseudotyped HIV-Luc viruses, 
Nef7.A3G-containing viruses showed a significantly lower level of viral infection than all 
others.  Moreover, we also infected U87.CD4.CXCR4 and U87.CD4.CCR5 cells with 
VSV-G-pseudotyped viruses carrying the respective proteins and obtained similar results 
(Fig. 20).  The inhibition is not complete, most likely because while fusion to Nef7 does 
partially restore virion incorporation of A3G, it cannot completely overcome the effect of 
Vif.   
 
1.9 Block of HIV-1 replication by Nef7.A3G-containing VLP   
CD4+ T lymphocytes are natural target cells for HIV-1 infection.  Thus, we next 
determined the feasibility of using Nef7.A3G to target and inhibit HIV-1 replication in 
Jurkat cells, a CD4+ human T lymphocyte cell line commonly used for HIV-1 infection.  
To ensure efficient delivery of Nef7.A3G into HIV-1 infected cells, we took advantage of 
the virus-like particles (VLP)-based inverse fusion strategy (Endres, Jaffer et al. 1997).  
We transfected 293T cells with an HIV-based packaging vector psPAX2 (Dull, Zufferey 
et al. 1998), Nef7.A3G, CD4, and CXCR4 and collected the cell culture supernatants as 
the VLP.  We also included WT Nef, Nef7, and A3G to produce control VLP.  CD4 and 
CXCR4 expression and presentation on the outer viral membrane allows recognition and 
binding to the gp120 that is expressed on the cell surface of HIV-1-infected cells, 
resulting in fusion of VLP with these cells and delivery of virion components within VLP 
into these cells (Endres, Jaffer et al. 1997).  We determined the VLP production from 
transfected 293T cells as measured by reverse transcriptase activity and examined each of 
the VLP for incorporation of Nef or A3G by Western blot as described above (Fig. 21).  
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Figure 20.  Effects of virion incorporation of Nef and its derivatives on the 
infectivity of VSV-G-pseudotyped HIV-Luc reporter viruses in U87 cells.  A.  293T 
cells were transfected with HIV-Luc, VSV-G, and WT Nef, Nef7, Nef7.A3G, or A3G 
expression plasmids with pcDNA3 included as a control.  At 72 hr post-transfection the 
viruses were collected and quantitated for RT activity.  Viruses with an equal level of RT 
activity were used to infect U87.CD4.CXCR4 cells, and the infected cells were harvested 
for the Luc activity assay 48 hr post infection.  B.  Similarly, HIV-Luc viruses carrying 
Nef and each of its derivatives were prepared and used to infect U87.CD4.CCR5 cells.  *: 
p<0.05, **: p<0.01.  Data were mean ± s.d. and representative of 3 independent 
experiments. 
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Figure 21.  VLP incorporation of Nef7.A3G.  293T cells were transfected with 
psPAX2, CD4, CXCR4, and WT Nef, Nef7, Nef7.A3G, or A3G expression plasmids 
with pcDNA3 included as a control.  Progeny viruses were collected at 72 hr post-
transfection quantified by reverse transcriptase assay, then subjected to Western blot 
analysis using an anti-HA antibody, with antibodies against HIV-1 p24 as a loading 
control.  Data were representative of two independent experiments. 
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We found that even in the context of VLP, Nef7 and Nef7.A3G exhibited high virion 
incorporation. 
 
We next infected Jurkat cells with replication-competent HIV-1 HXB2 viruses and 
exposed the infected cells to each of the VLP twice, once immediately following 
infection and once 24 hr later.  We then monitored HIV-1 infection and replication in 
these cells.  Notably, treatment of HIV-infected Jurkat cells with VLP that were derived 
from Nef7.A3G transfection gave rise to little viral replication (Fig. 22).  In contrast, 
treatment of VLP derived from cells expressing WT Nef, Nef7, and A3G all showed 
similar viral replication kinetics to that of VLP from pcDNA3 control.  The impact of 
Nef7.A3G is much higher in this context than in single-round infection assays (Fig. 18-
20) because the effect was amplified over eight days instead of just 72 hr.  To 
quantitatively compare the anti-HIV effects of these VLP, we stained the cells for HIV-1 
p24 at day 8 and counted the total number of cells and the number of p24+ cells.  All 
samples had a similar number of viable cells, i.e. about 1.2 x 107 cells.  Nef7.A3G-treated 
cells had 1.1  0.2% p24+ cells, while all others had 92.5  4.2% p24+ cells at day 8 post-
infection.  Thus, the anti-HIV activity of the Nef7.A3G was calculated to be about 107 in 
this particular experimental setting.  These results suggest that Nef7.A3G-containing 
VLP expressing CD4 and CXCR4 can successfully target HIV-infected cells and inhibit 
virus replication in HIV-1 infected Jurkat cells.   
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Figure 22.  Effects of Nef-, Nef7-, Nef7.A3G- and A3G-containing VLP on HIV-1 
replication.  293T cells were transfected with psPAX2, CD4, CXCR4, and WT Nef, 
Nef7, Nef7.A3G, or A3G expression plasmids.  At 72 hr post-transfection culture 
supernatants containing VLP were collected, cleared of cell debris, and quantitated for 
the RT activity.  CD4+ Jurkat T lymphocytes were first infected with HIV-1 HXB2 strain.  
At 3 hr the remaining viruses were removed from the cells by repeated washes with fresh 
medium and then treated with each of the VLP, followed by a second treatment 24 hr 
after the initial infection.  The cells were cultured for various lengths of time as indicated.  
At each time point, cell culture supernatant was collected and quantitated for RT activity.  
The RT activity of input VLP in the culture medium was marked as a dotted line.  *: 
p<0.05, **: p<0.01.  Data were mean ± s.d. and representative of 3 independent 
experiments. 
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PART 2: NEF ENHANCES THE FORMATION OF HIV-1 VIROLOGICAL 
SYNAPSES 
2.1 Nef increases the formation of VS 
To date, there has been no research done on the impact of HIV-1 accessory proteins on 
virological synapse formation.  Currently, the only viral protein known to be involved in 
the HIV-1 virological synapse is gp120, which initiates the formation through its 
interaction with CD4.  Because of its numerous important pathogenic functions in 
infected cells, many of which could potentially affect the VS, we investigated the effect 
of Nef on VS formation.  First, Jurkat T cells were infected with either WT HIV or a Nef-
deleted, replication-competent virus and cultured until close to 100% infection.  Infected 
cells were mixed with CFSE-labeled target cells and allowed to form virological synapses 
on coverslips, and then conjugates were stained with either p24 or gp120 and CD4 
antibodies.  Formation of virological synapses was identified by polarization of p24 at the 
interface between an infected cell and a CFSE-labeled target cell (Fig. 23A), allowing for 
the percentage of infected cells engaged in a VS to be determined (Fig. 23B).  The 
percentage of cells infected with HIVΔNef was significantly lower than that of cells 
infected with WT virus.  We also performed experiments staining for co- localization of 
gp120 and CD4 and obtained similar results. 
 
2.2 Piceatannol titration 
Next, we determined whether the impaired ability of Nef-defective HIV-1 viruses to form 
synapses translated to a decrease in their ability to transfer virions to target cells.  
However, we wished to use piceatannol, a Syk tyrosine kinase inhibitor that is a  
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Figure 23.  Nef effect on virological synapse formation in HIV-infected Jurkat cells.  
A.  Jurkat cells were infected with WT HIV or HIVΔNef and cultured until close to 100% 
of cells were infected.  Uninfected cells were labeled with CFSE, and 0.5 x 106 
uninfected cells were incubated with 0.5 x 106 infected cells for 1.5 hr on poly-L-lysine 
treated coverslips, in 200 μl total RPMI to allow for VS formation.  Cells were then fixed 
and stained for p24. A representative VS is shown.  B.  The percentage of infected cells 
involved in a VS was determined for each virus.  *: p<0.05.  Data were mean ± s.d. and 
representative of 4 independent experiments. 
 
 112 
particularly effective inhibitor of the VS component ZAP70, as a negative control of VS-
dependent virus transfer.  Since piceatannol can be toxic at high concentrations and our 
experiment required its activity for 24 hr, we first determined the concentration of 
piceatannol that would inhibit ZAP70 phosphorylation at 24 hr with minimal 
cytotoxicity.  We treated uninfected, WT HIV-infected, and HIVΔNef infected Jurkat 
cells with increasing concentrations of piceatannol for 24 hr.  We then determined the 
percentage of dead cells by trypan blue staining and found that piceatannol seemed to 
have increased cytotoxicity in infected cells, possibly due to the additional stress these 
cells were already under (Fig. 24A).  Cytotoxicity increases slightly at 10 μg/ml 
piceatannol and stays approximately the same until 40 μg/ml piceatannol where it 
increases dramatically.  Lysis of the treated cells followed by immunoprecipitation for 
phospho-tyrosine and Western blot of ZAP70 showed that p-ZAP70 decreases steadily 
with increasing piceatannol treatment, with no detectable pZAP70 found in the 30 μg/ml 
sample (Fig. 24B).  Treatment with piceatannol did not affect overall ZAP70 expression.  
We therefore used 30 μg/ml piceatannol in the following experiments as treatment at this 
concentration resulted in no detectable ZAP70 activation while minimizing cytotoxicity.   
 
2.3 Nef increases Gag transfer to target cells 
Next, we analyzed the increase of gag expression in target cells over increasing periods 
of VS formation.  We cultured Jurkat cells infected with WT HIV or HIVΔNef until they 
were close to 100% infected, and then mixed washed infected cells with CFSE-labeled 
target cells in a 1:1 ratio for increasing timepoints.  After co-incubation, cells were fixed 
and stained for p24 to determine the percentage of p24+ target cells (Fig. 25A).  We 
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Figure 24.  Piceatannol titration in HIV-infected Jurkat cells.  A.  Jurkat cells were 
infected with WT HIV or HIVΔNef and cultured until close to 100% infection, with 
uninfected cells included as a control.  1 x 106 cells were then cultured in 96-well plates 
in the presence of increasing concentrations of piceatannol.  After 24 hr incubation, the 
percentage of dead cells was determined using trypan blue staining.  B.   Jurkat cells were 
infected with WT HIV or HIVΔNef and cultured until close to 100% infection, with 
uninfected cells (U) included as a control.  6 x 106 cells were then cultured in T25 flasks 
in the presence of increasing concentrations of piceatannol.  After 24 hr incubation, the 
cells were lysed and subjected to phosphotyrosine immunoprecipitation, followed by 
Western blot for ZAP70, and then pTyr.  A phosphotyrosine band of ~55 kDa that was 
not affected by Nef expression was chosen as a loading control.  Western blotting against 
ZAP70 was also performed and normalized to actin.  *: p<0.05 as compared to untreated 
uninfected sample; **: p<0.05 as compared to untreated HIVΔNef-infected sample; $: 
p<0.05 as compared to untreated WT HIV-infected sample.  Data were mean ± s.d. and 
representative of two independent experiments.  
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found that HIVΔNef infected cells transferred fewer virions to target cells during co-
culture than cells infected with WT HIV, with increasing differences over time (Fig. 
25B).  The transfer efficiency of HIVΔNef-infected cells after 24 hr is equivalent to that 
of WT HIV in the presence of cytochalasin D, an actin depolymerizer that is known to 
inhibit VS transfer of viral particles (Jolly, Kashefi et al. 2004), but greater than WT HIV 
transfer in the presence of piceatannol, which greatly inhibits the activity of ZAP70, a 
necessary component of VS-dependent viral transfer (Fig. 25C).  
 
2.4 Nef increases replication kinetics in conditions favoring VS formation 
To see whether Nef’s effect on virological synapse formation resulted in differences in 
viral spread over longer periods, we monitored replication kinetics in a situation that 
promoted virological synapse-dependent virus spread over cell-free virus spread: 1 x 106 
cells/ml resulting in an effective monolayer, with approximately 33% p24+ (infected) 
cells at the start of the experiment (Fig. 26A).  Because of the possibility that viral 
infection through virological synapses can be partially fusion-independent, the fusion 
inhibitor T-20 was also added to one set to eliminate any viral spread resulting from cell-
free virus.  We found that in these VS-favorable conditions there is a small but 
statistically significant lag in the replication kinetics of HIVΔNef infections as compared 
to WT infections (Fig. 26B).  This lag becomes more pronounced and longer-lived when 
T-20 is included to eliminate any cell-free infections (Fig. 26C).  Taken together, these 
results indicate that while not strictly necessary for virological synapse formation and 
synapse-dependent transfer of HIV-1 to target cells, Nef does indeed enhance the  
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Figure 25.  Nef effect on virological synapse-mediated Gag transfer.  A.  Jurkat cells 
were infected with HIVΔNef or WT HIV viruses and cultured until close to 100% of cells 
were infected.  Uninfected cells were labeled with CFSE, and 0.5 x 106 uninfected cells 
were incubated with 0.5 x 106 infected cells in 96-well plates, with 200 μl total RPMI for 
the indicated timepoints, with or without cytochalasin D or piceatannol.  Cells were then 
fixed, permeabilized, and stained for p24, then analyzed by flow cytometry to determine 
the transfer of HIV to target cells.  Representative dot plots are shown gated for CFSE 
(target cells).  B.  The percentage of Gag+ target cells was determined.  C. A 
representation of the 24 hr timepoint is shown.  *: p<0.05.  Data were mean ± s.d and 
representative of 4 independent experiments. 
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Figure 26.  Nef effect on HIV replication kinetics in conditions favoring VS 
formation.  A.  Jurkat T cells were infected with either HIVΔNef or WT HIV viruses and 
cultured until close to 100% of cells were infected as determined by p24 staining.  B.  
Infected cells were washed and incubated with uninfected cells in a 1:3 ratio at a 
concentration of 1 x 106 cells/ml in 24-well plates and virus production was monitored 
daily by RT assay of the supernatants.  C.  Infected cells were washed and incubated with 
uninfected cells as described above with the addition of 100 μg/ml T-20.  *: p<0.05.  
Data were mean ± s.d. and representative of 3 independent experiments. 
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formation of virological synapses, and this enhancement leads to increased replication 
kinetics when cell-cell viral spread is the predominant mode of viral transmission.  
 
2.5 Nef induces polarization of VS components 
2.5.1 Polarization in transfected 293T cells 
The next step was to investigate the differences between WT and HIVΔNef virological 
synapses that might account for the observed changes in VS formation and VS-dependent 
viral transfer.  Because of the previously identified importance of GM1 and CD81 in both 
immunological and virological synapse formation, we first examined the effect of Nef on 
lipid raft and CD81 distribution.  Thus, we transfected 293T cells with GFP or Nef-GFP 
and stained for either CD81 or GM1, a lipid raft marker.  Confocal microscopy analysis 
of the transfected cells showed that while both CD81 and GM1 were evenly distributed 
around the cell in GFP-expressing cells, in the majority of Nef-expressing cells CD81 
was polarized to one side of the cell (Fig. 27A) while GM1 tended to form one or two 
large clusters instead of many small, evenly distributed rafts as seen in GFP-expressing 
cells (Fig. 27B).   
 
We next examined the membrane expression patterns of both CD81 and GM1 by flow 
cytometry.  We reasoned that congregation of fluorophores exhibits brighter fluorescence 
intensity than evenly distributed fluorophores, and the resulting shift in fluorescence 
intensity detected by FACS would allow for a quantifiable measurement of changes of 
CD81 and GM1 expression patterns.  We therefore transfected 293T cells with GFP or 
Nef-GFP, stained for CD81 or GM1, and measured the staining intensity of GFP+ cells.  
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Figure 27.  Effect of Nef on distribution of virological synapse components as shown 
by confocal microscopy.  A.  293T cells were transfected with GFP or Nef-GFP.  At 48 
hr post-transfection, 0.5 x 106 cells were seeded onto ploy-L-lysine coated coverslips and 
allowed to attach for 3 hr.  The cells were then fixed and stained for CD81.  B.  GFP- and 
Nef-GFP-transfected cells were seeded onto coverslips and as above and stained for 
GM1.  Data were representative of 3 independent experiments, with at least 75 cells 
examined for each condition. 
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We found that expression of Nef led to an approximately 1.5-fold increase in the staining 
intensity of both CD81 (Fig. 28) and GM1 (Fig. 29).  Since virological synapse formation 
is dependent upon cytoskeletal dynamics, we also treated a set of transfections with 
cytochalasin D for 1 hr before analysis.  We found that cytochalasin D treatment did not 
affect polarization of either CD81 or GM1, indicating that retention of the polarized 
phenotype did not require actin remodeling, at least in short term.  However, by the time 
cytochalasin D was added to these cells polarization had already been established, and 1 
hr of treatment may not have been long enough for disassembly to occur.  Longer 
treatment of transfected cells with cytochalasin D was not possible due to the cell type 
used in these experiments; adherent cells depend upon actin to remain attached to the 
plate and healthy, so longer treatment resulted in cell death.  However, when we 
replicated these experiments in Jurkat cells later we were able to treat with cytochalasin 
D for 16 hr without adversely affecting the cells, and found that polarization was indeed 
actin-dependent.  
 
2.5.2 Surface localization of VS components 
Next, we needed to confirm that our flow cytometry polarization assay was an accurate 
measurement of polarization; namely, that Nef was not in fact altering the surface 
expression of either CD81 or GM1 and the increased intensity was indeed a result of 
polarization.  To do this, we examined the total cellular expression of CD81 in GFP or 
Nef-GFP stable Jurkat cell lines and found that the expression of Nef does not affect the 
overall level of CD81 (Fig. 30A).  We next examined just the membrane fraction of these 
cells to determine whether Nef affected the surface expression of CD81 or GM1, and 
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Figure 28.  Effect of Nef on the membrane distribution of CD81 as measured by flow 
cytometry.  A.  293T cells were transfected with GFP or Nef-GFP and harvested 48 hr 
later, with 1 μM cytochalasin D added to one set of samples 1 hr prior to harvesting.  
Cells were fixed and stained for CD81, then gated for GFP+ cells and analyzed by flow 
cytometry for CD81 intensity.  B.  The fold change in CD81 intensity was determined, 
with untreated GFP set to 1.  *: p<0.05.  Data were mean ± s.d and representative of 3 
independent experiments. 
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Figure 29.  Effect of Nef on the membrane distribution of GM1 as measured by flow 
cytometry.  A.  293T cells were transfected with GFP or Nef-GFP and harvested 48 hr 
later, with 1 μM cytochalasin D added to one set of samples 1 hr prior to harvesting.  
Cells were fixed and stained for GM1, then gated for GFP+ cells and analyzed by flow 
cytometry for GM1 intensity.  B.  The fold change in GM1 intensity was determined, 
with untreated GFP set to 1.  *: p<0.05.  Data were mean ± s.d. and representative of 3 
independent experiments. 
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Figure 30.  Effect of Nef on the total cellular and membrane expression of CD81 or 
GM1.  A.  Jurkat cells stably expressing GFP or Nef-GFP were lysed and analyzed for 
CD81 expression, with β-actin used as a loading control.  B.  GFP and Nef-GFP stable 
cell lines were lysed in hypotonic buffer, and membrane fractions were obtained through 
further centrifugation of the supernatant.  Membranes were analyzed for CD81 
expression by Western blot and GM1 expression by slot blot, with calnexin used as a 
loading control.  C.  GFP and Nef-GFP stable cell lines were fixed and stained for GM1 
or CD3 then gated for GFP+ cells and analyzed by flow cytometry for GM1 or CD3 
intensity.  The fold change in GM1 or CD3 intensity was determined, with GFP set to 1.  
*: p<0.05.  Data were mean ± s.d. and representative of 2 independent experiments. 
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found that there was again no detectable difference in either CD81 or GM1 surface 
expression (Fig. 30B).  Additionally, we performed our GM1 polarization assay with 
CD3 as a control, and found that Nef expression did not increase CD3 intensity.  
Therefore, we concluded that our flow cytometry assay was indeed an accurate means of 
determining Nef-induced polarization of VS components and that the higher intensity 
was due to the increased brightness inherent in denser expression patterns as opposed to 
diffuse expression. 
 
2.5.3 MβCD titration 
In order to confirm our results indicating that Nef induces polarization of lipid rafts, we 
needed to confirm that the large clusters of GM1 staining observed were, in fact, lipid 
rafts and not staining artifacts.  Methyl-β-cyclodextrin MβCD destabilizes lipid rafts by 
extracting the cholesterol from the membrane, and we utilized this as a negative control 
for GM1 staining.  Once extracted from the membrane, lipids localize to cytosolic lipid 
droplets, so the effectiveness of MβCD treatment can be determined by Oil Red O (ORO) 
staining (Subramaniyam, Zhou et al. 2010).  First we determined the appropriate 
concentration of (MβCD) to use.  Therefore, we seeded 293T cells onto poly-L-lysine 
treated coverslips, and treated them with increasing concentrations of MβCD, followed 
by ORO staining (Fig. 31A).  Lipid droplets started appearing at 6 μM MβCD, increased 
in number and size at 8 μM MβCD, and stayed about the same after that.  However, at 10 
μM MβCD there was noticeable cell death and unhealthy-looking cells, so we chose to 
use 8 μM MβCD in our experiments.  We next treated Jurkat cells with 8 μM MβCD to 
confirm that this concentration also worked in these cells.  Unfortunately, Jurkat cells 
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Figure 31.  MβCD titration in 293T and Jurkat cells.  A.  293T cells were transfected 
with GFP.  At 48 hr post-transfection, 1 x 106 cells were seeded onto poly-L-lysine-
coated coverslips and allowed to attach for 3 hr.  Cells were treated with increasing 
concentrations of MβCD for 1 hr, fixed, and stained by ORO.  B.  1 x 106 Jurkat cells 
were seeded onto poly-L-lysine-coated coverslips and treated with 8 μM MβCD for 1 hr, 
then fixed and stained by ORO, followed by DAPI.  Data were representative of two 
independent experiments. 
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contain very little cytoplasm so lipid droplets were not easily detectable (Fig. 31B), but 
there was no cell death using this concentration of MβCD. 
 
2.5.4 Polarization of VS components in Jurkat T cells 
Since the biologically relevant cell type in HIV-1 infections are CD4+ T lymphocytes, we  
confirmed that the Nef-induced polarization of CD81 and GM1 that we observed in 
transfected 293T cells was also present in Nef-expressing Jurkat cells.  To confirm our 
GM1 staining in Jurkat cells, we took advantage of a previously constructed panel of 
Jurkat cell lines stably expressing Nef-mutant-GFP fusion proteins for further analysis of 
the effect of Nef on virological synapse components.  We found that, as with the 
transfected cells, in the majority of Nef-expressing cells GM1 staining showed a large 
clustering of lipid rafts, whereas GFP-expressing cells exhibited a uniform distribution of 
small rafts along the cell surface (Fig. 32A).  To ensure that these bright spots were 
indeed large clusters of lipid rafts, we also treated the cells with (MβCD), which 
destabilizes lipid rafts by extracting the cholesterol from the membrane.  In the MβCD-
treated cells GM1 was found to be uniformly distributed around the membrane of both 
GFP- and Nef-expressing cells, indicating that the large GM1 spots were actually rafts 
(Fig. 32B).  Upon staining with CD81, confocal microscopy revealed that CD81 exhibits 
polarization similar to that of GM1 in Nef-expressing cells (Fig. 33A).  To ensure that 
this phenomenon was specific to virological synapse components and not a general 
polarization of cell surface proteins, we also stained for surface CD3, which has been 
shown to be absent from virological synapses and is not downregulated by Nef under  
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Figure 32.  Nef effect on the distribution of GM1 in Jurkat cells as shown by 
confocal microscopy.  A.  Jurkat cells stably expressing GFP or Nef-GFP were seeded 
onto ploy-L-lysine coated coverslips at a density of 1 x 106 cells/ml and allowed to attach 
for 1.5 hr, then fixed and stained for GM1.  B.  GFP- and Nef-GFP-expressing cells were 
seeded onto coverslips as above, treated with 8 mM MβCD for 1 hr, and stained for 
GM1.  Data were representative of 3 independent experiments. 
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Figure 33.  Nef effect on the distribution of CD81 in Jurkat cells as shown by 
confocal microscopy.  A.  Jurkat cells stably expressing GFP or Nef-GFP were seeded 
onto ploy-L-lysine coated coverslips at a density of 1 x 106 cells/ml and allowed to attach 
for 1.5 hr, then fixed and stained for CD81.  B.  GFP- and Nef-GFP-expressing cells were 
seeded onto coverslips as above and stained for CD3.  Data were representative of 3 
independent experiments. 
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normal circumstances.  The surface distribution of CD3 was not affected by Nef 
expression, suggesting that polarization is specific to VS components (Fig. 33B). 
 
We next confirmed GM1 and CD81 polarization in Jurkat cells using our flow cytometry 
polarization strategy.  We examined the GM1 and CD81 intensity of all five of our stable 
Jurkat cell lines.  Both WT Nef and the SH3-binding domain mutant (NefΔSH3) showed 
significantly higher GM1 (Fig. 34A) and CD81 (Fig. 34B) intensity than the GFP control.  
Conversely, removal of either the N-terminal basic region (NefΔbasic) or the 
myristoylation site (NefGG/VD) resulted in GM1/CD81 intensity similar to that of the 
GFP control, indicating that both the basic region of Nef and its myristoylation, but not 
the Nef SH3-binding domain, are necessary for Nef-induced lipid raft clustering.   
 
Since Jurkat cells are not as dependent upon the actin cytoskeleton to remain healthy as 
293T cells, we were able to determine the contribution of actin reorganizations to 
polarization by cytochalasin D treatment for longer timepoints.  We found that after 16 hr 
incubation with cytochalasin D all GM1 and CD81 clustering was abolished, indicating 
that this polarization is indeed driven by actin reorganizations.  Because ZAP70 
activation is required for VS-dependent transfer, we then determined whether the 
polarization of VS components would be affected by piceatannol treatment.  We 
performed the flow cytometry polarization assay after treatment with 30 μg/ml 
piceatannol and found that while GM1 showed decreased intensity changes upon 
piceatannol treatment, it was still significantly higher than that of GFP-expressing cells 
(Fig. 35A).  However, upon close examination, we found that the overall GM1 intensity  
 139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* *
A
B
*
*
 140 
 
 
 
 
 
 
 
Figure 34.  Effect of Nef on the membrane distribution of GM1 and CD81 in Jurkat 
cells as measured by flow cytometry.  A.  Jurkat cells stably expressing GFP, Nef-GFP, 
or Nef-GFP mutants were seeded into 24-well plates at a density of 1 x 106 cells/ml and 
incubated overnight with or without 1 μM cytochalasin D.  Cells were fixed and stained 
for GM1, then gated for GFP+ cells and analyzed by flow cytometry for GM1 intensity.   
The fold change in GM1 intensity was determined, with untreated GFP set to 1.  B.  
Stable Jurkat cell lines were treated as above but stained with CD81, and the fold change 
in CD81 intensity was determined, with untreated GFP set to 1.  *: p<0.05.  Data were 
mean ± s.d. and representative of 4 independent experiments. 
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Figure 35.  Effect of piceatannol on Nef-induced alteration in GM1 membrane 
distribution.  A.  Jurkat cells stably expressing GFP, Nef-GFP, or Nef-GFP mutants 
were seeded into 24-well plates at a density of 1 x 106 cells/ml and incubated overnight 
with or without 30 μg/ml piceatannol.  Cells were fixed and stained for GM1, then gated 
for GFP+ cells and analyzed by flow cytometry for GM1 intensity.  The fold change in 
GM1 intensity was determined, with untreated GFP set to 1.  B.  Stable Jurkat cell lines 
were treated with piceatannol as above, then seeded onto poly-L-lysine coated coverslips, 
allowed to attach for 1.5 hr, and fixed.  Autofluorescence was detected using confocal 
microscopy.  *: p<0.05.  Data were mean ± s.d. and representative of 2 independent 
experiments. 
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of GFP-expressing cells was significantly higher after piceatannol treatment as compared 
to untreated cells, indicating that treatment increased the background intensity of GM1 
staining.  Since this assay measures small changes in the intensity of GM1 staining with 
and without Nef, any increase in the background level of staining would result in a 
smaller fold increase in intensity.  This likely is what resulted in the lower change in 
GM1 intensity in piceatannol-treated Nef-expressing cells.  To confirm that piceatannol 
causes autofluorescence, we examined piceatannol-treated GFP-expressing cells using 
confocal microscopy and found that while unstained, untreated GFP-expressing cells did 
not show any red color, the unstained treated cells did show easily detectable red 
fluorescence (Fig. 35B). 
 
As an additional confirmation of the effect of Nef on lipid raft distribution, we next 
performed membrane fractionation or raft floatation assays.  Slot blot analysis of 
membrane fractions showed that a larger percentage of GM1 localized to less dense 
fractions in Nef-expressing cells as compared to GFP-expressing cells (Fig. 36).  Since 
lipid rafts localize to higher fractions due to their decreased density as compared to the 
surrounding non-raft membrane, the larger percentage of GM1 in the less dense fractions 
further supports the existence of larger lipid rafts, as larger rafts will exhibit an even 
greater decrease in density as compared to non-raft membranes.  Since CD81 is known to 
localize largely to lipid rafts, we were also able to use this assay to confirm the effects of 
Nef on CD81 polarization.  We found that CD81 also localized more to less dense 
fractions in Nef-expressing cells as compared to GFP-expressing cells (Fig 37).  In 
contrast, CD3 distribution was not affected and remained within smaller rafts.  Analysis  
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Figure 36.  Membrane fractionation in the presence and absence of Nef.  A.  Jurkat 
cells stably expressing GFP or Nef-GFP were seeded into 6-well plates at a density of 1 x 
106 cells/ml and incubated overnight.  One hour prior to harvesting, control cells were 
treated with 8 μM MβCD.  The cells were cooled on ice for 20 min, then lysed in lipid 
raft lysis buffer and loaded onto a sucrose gradient for lipid raft fractionation, with 0.5 ml 
aliquots taken from the top after centrifugation.  Aliquoted fractions were analyzed by 
GM1 slot blot.  B.  The percentage of total GM1 in each fraction was determined.  Data 
were representative of 4 independent experiments. 
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Figure 37.  CD81 localization during membrane fractionation in the presence of Nef.  
A.  Jurkat cells stably expressing GFP or Nef-GFP were seeded into 6-well plates at a 
density of 1 x 106 cells/ml and incubated overnight.  The cells were cooled on ice for 20 
min, then lysed in lipid raft lysis buffer and loaded onto a sucrose gradient for lipid raft 
fractionation, with 0.5 ml aliquots taken from the top after centrifugation.  Aliquoted 
fractions were analyzed by slot blot for CD81, CD3, and GFP.  B.  The percentage of 
total CD81, CD3, and GFP in each fraction was determined.  Data were representative of 
2 independent experiments. 
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of these fractions for GFP shows that GFP is almost exclusively present in the cytoplasm, 
while Nef-GFP localized strongly to lipid rafts, although it is also present to a great 
extent in the cytoplasm (Fig. 37). 
 
2.5.5 Polarization of ZAP70 
At this point, all the VS components examined were membrane molecules.  Therefore, 
we then determined what effect Nef had on the localization of intracellular virological 
synapse components.  ZAP70 tyrosine kinase is the only intracellular host protein other 
than actin that is known to be involved in the virological synapse; additionally, Nef is 
known to affect the distribution of ZAP70 during a signaling cascade resulting in MHC I 
downregulation.  Therefore, we examined the cellular distribution of both ZAP70 and 
total phosphotyrosine in cells involved in virological synapses.  We found that pTyr 
localized to the VS significantly more efficiently in WT HIV infected cells than in 
HIVΔNef infected cells (Fig. 38).  Interestingly, p24 showed a similar pattern, suggesting 
that the two were recruited to the VS together.  The pTyr localized to virological 
synapses is at least partially comprised of ZAP70, as ZAP70 staining shows an identical 
pattern of polarization (Fig. 39).  This indicates that Nef expression alters the distribution 
of intracellular VS components as well as that of surface components. 
 
2.6 Nef induces formation of actin protrusions 
Because of the importance of actin dynamics in both virological synapse formation and 
Nef-induced polarization of VS components we examined the distribution of F-actin, the 
form of actin responsible for the formation of membrane structures such as filopodia and  
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Figure 38.  Nef effect on the localization of pTyr to virological synapses.  A.  Jurkat 
cells were infected with WT HIV or HIVΔNef and cultured until close to 100% of cells 
were infected.  Uninfected cells were incubated with infected cells in a 1:1 ratio, with 1 x 
106 cells in 200 μl RPMI for 1.5 hr on poly-L-lysine treated coverslips to allow for VS 
formation.  Cells were then fixed, permeabilized, and stained for p24 and total pTyr.  B.  
The percentage of total pTyr that localized to the VS was quantified using Metamorph 
software.  *: p<0.01.  Data were mean ± s.d. and representative of 4 independent 
experiments. 
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Figure 39.  Nef effect on the localization of ZAP70 to virological synapses.  A.  Jurkat 
cells were infected with WT HIV or HIVΔNef and cultured until close to 100% of cells 
were infected.  Uninfected cells were incubated with infected cells in a 1:1 ratio, with 1 x 
106 cells in 200 μl RPMI for 1.5 hr on poly-L-lysine treated coverslips to allow for VS 
formation.  Cells were then fixed, permeabilized, and stained for p24 and ZAP70.  B.  
The percentage of total ZAP70 that localized to the VS was quantified using Metamorph 
software.  *: p<0.05.  Data were mean ± s.d. and representative of 4 independent 
experiments. 
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ruffles, in each of the mutant Nef cell lines and found that Nef induced actin protrusions 
(Fig. 40A).  These structures have since been reported in multiple studies, and have been 
shown to transfer Nef to target cells (Nobile, Rudnicka et al.; Xu, Santini et al. 2009).  
Our data further reveals that the SH3-binding domain of Nef and its myristoylation are 
required for formation of these protrusions.  Interestingly, both the protrusions formed in 
Nef-expressing cells and the abortive protrusions formed in NefΔSH3-expressing cells 
appeared to be localized predominantly to one side of the cell.  However, while the 
NefΔbasic cells were capable of forming actin protrusions, they were much thinner than 
those in WT Nef-expressing cells and were evenly distributed around the cell.  This 
supports our data that the basic region of Nef is involved in polarizing cells (Fig. 34) and 
also suggests that there is a separate mechanism responsible for the formation of actin 
protrusions as the requirements for these two processes are different. 
 
We theorized that these actin protrusions could be involved in either the establishment of 
virological synapses or the transfer of virions through virological synapses.  Therefore, 
because of its involvement in viral transfer via VS, we wanted to determine the 
importance of ZAP70 on the formation of these protrusions.  We found that treatment of 
piceatannol completely abolished all actin protrusions (Fig. 40B), indicating that ZAP70 
was necessary for their formation and supporting the theory that they are indicative of VS 
transfer.  Furthermore, close examination of the confocal data shows that although there 
are no protrusions formed after piceatannol treatment, F-actin distribution follows the 
same pattern as mentioned above; namely, that in WT Nef and NefΔSH3-expressing cells 
actin is polarized while NefΔbasic cells show an even distribution of F-actin around the 
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Figure 40.  Nef effect on actin organization.  A.  Jurkat cells stably expressing GFP or 
Nef-GFP mutants were seeded onto poly-L-lysine-coated coverslips at a density of 1 x 
106 cells/ml and allowed to adhere for 1.5 hr, then fixed, permeabilized, and stained for 
F-actin.  B.  Stable Jurkat cell lines were treated with 30 μg/ml piceatannol for 24 hr at a 
density of 1 x 106 cells/ml, then seeded onto coverslips and stained as described above.  
Data were representative of 3 independent experiments. 
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periphery of the cell.  This further confirms the requirements for Nef-mediated 
polarization of VS components and also confirms that there are separate requirements for 
polarization and transfer. 
 
In an effort to confirm that these protrusions form in infected cells and that they are the 
same that are responsible for transferring Nef to target cells, we infected Jurkat cells with 
WT HIV and HIVΔNef, co-cultured them with target cells, and then stained for Nef (Fig. 
41).  When infected and uninfected cells were in close contact very few Nef-containing 
protrusions were observed, but when the cell density was lower the number of protrusions 
increased until approximately 5% of WT HIV infected cells exhibited protrusions 
connecting them to uninfected cells.  We were able to detect Nef within the protrusions, 
and these were only found in WT HIV-infected cells as shown previously (Xu, Santini et 
al. 2009).  Therefore, we concluded that the Nef-induced protrusions observed here are a 
means of transferring materials from the infected cell to an uninfected bystander cell. 
 
2.7 VS formation using Nef mutant viruses 
Based on these findings we constructed a series of replication-competent Nef mutant 
viruses to further elucidate the mechanism of Nef enhancement of VS-dependent viral 
transfer (Fig. 42).  Using these mutants we examined both the percentage of infected cells 
involved in synapses (Fig. 43) and the Gag transfer to target cells (Fig. 44).  Our data 
shows that Nef-mediated recruitment of Vav (HIV.nef-F191A) and a functional SH3-
binding domain (HIV.nef-AxxA) are necessary for proper VS formation and viral transfer.  
Interestingly, even though Nef results in greater localization of ZAP70 to the VS as  
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Figure 41.  Nef transfer to neighboring cells.  Jurkat cells were infected with WT HIV 
or HIVΔNef and cultured until close to 100% of cells were infected.  Infected cells were 
washed and incubated with uninfected cells in a 1:1 ratio, 1 x 106 total cells in 200 μl 
RPMI, for 4 hr on poly-L-lysine treated coverslips to allow for Nef transfer.  Cells were 
then fixed, permeabilized, and stained for Nef, then stained with DAPI.  Data were 
representative of 2 independent experiments. 
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Figure 42.  Replication-competent Nef mutant viruses.  A.  Plasmid map, B.  mutation 
site, and C.  function affected for replication-competent Nef mutant virus constructs.  Nef 
structure adapted from Doms and Trono 2000 who compiled the proposed structure based 
on data from Grzesiek, Bax et al. 1996; Lee, Saksela et al. 1996; Barnham, Monks et al. 
1997.
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Figure 43.  Nef residues important for VS formation.  Jurkat cells were infected with 
WT HIV, HIVΔNef, or each of the Nef mutant viruses and cultured until close to 100% 
of cells were infected.  Uninfected cells were labeled with CFSE and incubated with 
infected cells in a 1:1 ratio, 1 x 106 total cells in 200 μl RPMI, for 1.5 hr on poly-L-lysine 
treated coverslips to allow for VS formation.  Cells were then fixed, permeabilized, and 
stained for p24, and the percentage of infected cells involved in a VS was determined for 
each virus.  *: p<0.05.  Data were mean ± s.d. and representative of 3 independent 
experiments. 
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Figure 44.  Nef residues important for VS-dependent virus transfer.  A.  Jurkat cells 
were infected with HIVΔNef, WT HIV, or Nef mutant viruses and cultured until close to 
100% of cells were infected.  Uninfected cells were labeled with CFSE and incubated 
with infected cells in a 1:1 ratio, 1 x 106 total cells in 200 μl RPMI in 96-well plates, for 
the indicated timepoints.  Cells were then fixed, permeabilized, and stained for p24, then 
analyzed by flow cytometry to determine the percentage of Gag+ target cells.  B. A 
representation of the 24 hr timepoint is shown.  *: p<0.05.  Data were mean ± s.d. and 
representative of 3 independent experiments. 
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shown above, direct Nef-mediated recruitment of ZAP70 (HIV.nef-62AAAA65) is not 
necessary for VS formation.  This suggests that there is an indirect mechanism for ZAP70 
recruitment to the virological synapse, possibly via its localization to lipid rafts.   
 
Because Vav is a well-known regulator of actin dynamics, we theorized that Nef-
mediated recruitment of Vav to a signaling complex might be a key step in the 
polarization of synapse components that we had previously observed.  We tested this 
theory by examining the GM1 intensity of infected cells and found that the HIV.nef-
F191A mutation does indeed abolish Nef-mediated polarization (Fig. 45).  To determine 
at which point the HIV.nef-AxxA is needed for the virological synapse, we looked at the 
levels of activated ZAP70 in cells infected with each of the HIV-1 mutants.  We 
subjected infected Jurkat cell lysates to phosphotyrosine immunoprecipitation, followed 
by ZAP70 Western blot (Fig. 46).  The results showed that, as expected, WT HIV 
increases the phosphorylation of ZAP70, while HIVΔNef has pZAP70 levels similar to 
uninfected cells.  The HIV.nef-F191A mutant had no significant decrease in pZAP70 
levels, consistent with our findings that polarization did not require ZAP70, while both 
HIV.nef-AxxA and HIV.nef-62AAAA65 exhibited decreased phosphorylation of ZAP70, 
though not to the extent of HIVΔNef.   
 
2.8 VS formation in PBMC 
Finally, we confirmed these findings using primary cells.  Therefore, we isolated PBMC 
and, following activation infected them with WT HIV and each of our Nef mutant 
viruses.  We analyzed each infection for number of virological synapses formed 
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Figure 45.  Nef residues necessary for GM1 polarization.  Jurkat cells were infected 
with HIVΔNef, WT HIV, or Nef mutant viruses and cultured until 100% of cells were 
infected, and 1 x 106 cells were fixed and stained for GM1, then analyzed by flow 
cytometry for GM1 intensity.  The fold change in GM1 intensity was determined, with 
HIVΔNef set to 1.  *: p<0.05.  Data were mean ± s.d. and representative of 3 independent 
experiments. 
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Figure 46.  Relationship between Nef-induced activation of ZAP70 and VS-
dependent transfer.  A.  Jurkat cells were infected with HIVΔNef, WT HIV, or Nef 
mutant viruses and cultured until 100% of cells were infected.  The cells were lysed and 
subjected to phosphotyrosine immunoprecipitation, followed by Western blot for ZAP70.  
B.  Densitometry analysis of pZAP70 was normalized using a phosphotyrosine band of 
~55 kDa that was not affected by Nef expression.  Western blot analysis was performed 
on ZAP70 normalized to actin.  *: p<0.05.  Data were mean ± s.d. and representative of 3 
independent experiments. 
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(Fig. 47A) and the percent Gag transfer (Fig. 47B) as described above for Jurkat cell 
infections.  We found that Nef increased the number of infected cells engaged in 
virological synapses in primary cells to an extent similar to that of Jurkat cells, while the 
difference in VS-dependent Gag transfer was even higher than that of Jurkat cells.   
 
Taken together, the data obtained from our experiments reveals that Nef is acting by two 
distinct mechanisms.  Firstly, Nef induces polarization of VS components through an 
actin-dependent process that requires its N-terminal basic region and myristoylation.  
This process is driven by Nef recruitment of Vav.  Secondly, Nef induces protrusions that 
require activation of ZAP70 to form, and likely are an indication of VS-dependent viral 
transfer.  Further analysis using replication-competent Nef mutant viruses showed that 
Nef-specific recruitment of ZAP70 was not involved in promoting VS formation or 
transfer; however, the Nef SH3-binding domain activated ZAP70, allowing the formation 
of actin protrusions.  When both pathways are active, the result is optimal formation of 
virological synapses and efficient transfer of virions to target cells at the synapses. 
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Figure 47.  Nef effect on VS formation in PBMC.  A.  Primary cells were infected with 
WT HIV, HIVΔNef, or Nef mutant viruses and cultured until close to 100% of cells were 
infected.  Uninfected cells were labeled with CFSE and incubated with infected cells in a 
1:1 ratio, 1 x 106 total cells in 200 μl RPMI, on poly-L-lysine-coated coverslips for 1.5 hr 
to allow for VS formation.  Cells were then fixed, permeabilized, and stained for p24, and 
the percentage of infected cells involved in a VS was determined for each virus type.  B.  
Additional CFSE-labeled target cells were incubated with infected cells in a 1:1 ratio, 1 x 
106 total cells in 200 μl RPMI in 96-well plates, for 24 hr and stained for p24 to 
determine the percentage of Gag+ target cells.  *: p<0.05.  Data were mean ± s.d. and 
representative of 3 independent experiments. 
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DISCUSSION 
 
Summary of the results 
The challenges of current anti-HIV treatments mandate development of alternative and 
novel anti-HIV therapies.  Nef is a very important HIV-1 protein, and its biggest 
pathogenic factor in vivo.  Therefore, in this study we focused on two different aspects of 
Nef: the virion incorporation of a Nef mutant called Nef7 and Nef’s role in virological 
synapse formation.  In the first part of the study, we confirmed that Nef7 incorporated 
into progeny virions at a higher level than WT Nef (Fig. 10), and demonstrated that 
Nef7.A3G also incorporated into HIV-1 virions to a similar extent (Fig. 13).  In contrast, 
A3G alone was present in virions in a very small amount when expressed in the presence 
of Vif.  The higher incorporation of Nef7.A3G over A3G alone was partially accounted 
for by a decreased ability of Vif to degrade the fusion protein, likely due to steric 
hindrance of Vif binding to A3G.  Fusion of A3G to Nef7 may have physically blocked 
Vif making its binding to A3G more difficult.  However, this slight increase in the 
cellular expression of Nef7.A3G over A3G is not enough to account for the large 
difference in virion incorporation.  Therefore, Nef7.A3G virion incorporation is likely 
largely due to the Nef7 phenotype.   
 
We further showed that the Nef7.A3G fusion protein retains the less pathogenic 
phenotype of Nef7, as Nef7.A3G fails to activate PAK2 or to downregulate CD4 or MHC 
I (Fig. 14, 15, 16).  Importantly, we show that the Nef7.A3G fusion protein retains the 
anti-HIV activity of A3G even in the context of HIV-1 Vif expression and is independent 
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of both the cell types used and the method of virion entry (Fig. 18, 19, 20).  Furthermore, 
we show that Nef7.A3G-containing VLP potently inhibit HIV-1 replication in Jurkat cells 
(Fig. 22). 
 
The next aspect of Nef function during HIV-1 infection that we investigated was what, if 
any, affect it had on HIV-1 virological synapses.  We first determined the ability of WT 
HIV and HIVΔNef to form virological synapses and found that there was a significantly 
decreased ability of HIV-1 to form synapses in the absence of Nef (Fig. 23).  This 
decreased ability to form virological synapses translated to a lower amount of Gag 
protein transferred to target cells (Fig. 25) as well as delayed replication kinetics in 
culture conditions that favor cell-cell replication over cell-free replication (Fig. 26). 
 
The ability of Nef to enhance the formation of virological synapses and the subsequent 
transfer of HIV-1 virions to target cell was confirmed in primary CD4+ T lymphocytes 
(Fig. 47).  In fact, the requirement for Nef appeared to be greater in primary cells than in 
cell lines, as WT HIV showed an approximately 63% increase in Gag transfer to target 
cells over HIVΔNef in primary cells, whereas in Jurkat cells the difference was 
approximately 50%. 
 
Further experiments revealed that Nef possessed two distinct abilities that could promote 
HIV-1 virological synapse formation and viral transfer.  The first involved polarization of 
many virological synapse components, including GM1, CD81, ZAP70, and p24 (Fig. 27- 
29, 32-34, 37-39).  The polarization of most of these is likely dependent upon lipid raft 
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clustering, as all of the mentioned components are localized to lipid rafts.  Furthermore, 
we found that Nef did not specifically recruit ZAP70 to the virological synapse, nor was 
there any indication that Nef directly affected the cellular localization of either CD81 or 
p24 (Fig. 43-45).  Polarization of lipid rafts was found to require the membrane 
localization of Nef and was promoted by Nef recruitment of Vav followed by Vav-
induced actin reorganization (Fig. 45).  ZAP70, however, was not involved in the process 
(Fig. 35). 
 
The second aspect of Nef that could promote virological synapse formation was its ability 
to form actin protrusions.  Formation of these protrusions required ZAP70 and is likely 
an indication of virological synapse-dependent viral transfer to target cells.  The Nef 
SH3-binding domain and Nef myristoylation are both required for this process, the first to 
ensure ZAP70 activation and the second to ensure the proper cellular localization of Nef 
(Fig. 40). 
 
Virion incorporation of Nef7 and Nef7 fusion proteins 
Nef7 has been previously shown to incorporate into viruses at an estimated 1100 
molecules per virion, as compared to the estimated 10 molecules of WT Nef per virion. 
They estimated the number of WT Nef molecules present in HIV virions by comparing 
the relative densities of the WT Nef and p24 bands, and then used this constant to 
estimate the number of Nef7 molecules present in HIV virions.  Because protein 
detection can become saturated this difference may not translate linearly to detection on 
Western blots, and the study did not determine fold incorporation by densitometry 
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analysis of the Western blots (Peretti, Schiavoni et al. 2005).  Using densitometry 
analysis our results showed higher virus incorporation of Nef7 than WT Nef by about 9 
fold, with both V153L and E177G point mutations being required for the increased 
incorporation (Fig. 10).  The higher virion incorporation of Nef7 is most likely due to its 
increased localization to lipid rafts; however, the mechanism behind this increased 
localization has yet to be determined.  Our results also show that Nef7.A3G maintains the 
higher virion incorporation property of Nef7 (Fig. 13).  A3G by itself was used as a 
control, and as expected, failed to encapsidate efficiently.  A recent study has shown that 
fusion of A3A, a Vif-resistant member of the APOBEC3 family that does not restrict 
HIV-1 infectivity to the HIV-1 protein Vpr resulted in the alteration of its virion 
localization from the matrix to the viral core, which granted Vpr.A3A anti-HIV activity 
(Aguiar, Lovsin et al. 2008).  A second recent study showed that fusion of A3G to a 
virion-targeting peptide derived from Vpr (R88-A3G) resulted in restriction of HIV-1 
infectivity (Ao, Yu et al. 2008).  This fusion protein is susceptible to Vif-mediated 
degradation, and its higher virion incorporation is due to increased R88-A3G targeting to 
the virion by the remaining undegraded R88-A3G.  Compared to Vpr, Nef7 is 
incorporated into virion at a higher level (Singh, Tungaturthi et al. 2001; Peretti, 
Schiavoni et al. 2005).  In addition, the higher level of virion incorporation of Nef7 as 
compared to WT Nef offers Nef7 an advantage over the native HIV-1 Nef protein for 
virion incorporation.  In contrast, Vpr.A3A and R88-A3G are likely to be equal in 
efficiency to the native HIV-1 Vpr protein in virion incorporation.  This is very important 
when the anti-viral activity of these chimeras is evaluated in the context of HIV-1 
infected cells.  Furthermore, our results showed that Nef7.A3G had anti-HIV activity in 
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both replication-defective single round HIV infection and the HIV-1 replication assay.  
However, whether Vpr-A3A would be an effective anti-HIV agent in the context of HIV-
1 replication is not established.   
 
Pathogenicity of Nef7 fusion proteins 
Aside from its virion incorporation, a key property of Nef7 that allows it to be used as a 
carrier for therapeutic proteins is its relative lack of toxicity.  While Nef is the most 
important pathogenic factor of HIV-1, Nef7 has been shown to be defective for a number 
of key Nef properties.  One of the best known characteristics of Nef is its ability to 
activate the cellular kinase PAK2, and disease progression in macaques has been 
associated with reversion of Nef mutants to a PAK2-activating phenotype (Khan, Sawai 
et al. 1998).  Previous work has shown that Nef7 does not activate PAK2 (D'Aloja, 
Santarcangelo et al. 2001), and our data supports that conclusion.  In an in vitro kinase 
assay, both Nef7 and the Nef7.A3G fusion protein failed to activate PAK2, confirming 
that Nef7 is less pathogenic than WT Nef and that fusion of A3G to Nef7 does not alter 
this phenotype (Fig. 14).  This loss of function does not appear to correlate with a loss of 
Nef7 binding to PAK2, as PAK2 is detected in immunoprecipitates of both Nef7 and 
Nef7.A3G.  Likewise, the expression of Nef7 does not affect the intracellular levels of 
PAK2.  Taken together, these data suggest that the loss of PAK2 activation in Nef7 is due 
to an inability of bound Nef7 to activate PAK2.  Our conclusion is in agreement with the 
study in which the Nef residues 85, 89, 187, 188, and 191 are found to be critical for Nef 
binding to PAK2 (Agopian, Wei et al. 2006), as none of these residues are affected in 
Nef7 as compared to WT Nef. 
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A second well known property of Nef, the downregulation of surface molecules such as 
CD4 and MHC I, has also been shown to be defective in Nef7 (D'Aloja, Santarcangelo et 
al. 2001).  Our results show that in HeLa cells WT Nef downregulates both CD4 and 
MHC I, with MHC I downregulation being much more efficient (Fig. 15, 16).  Both Nef7 
and Nef7.A3G show no significant decrease in the surface expression of either CD4 or 
MHC I.  Nef7 had previously been shown to downregulate CD4 slightly (D'Aloja, 
Santarcangelo et al. 2001), although much less efficiently than WT Nef.  In the system 
that we used, Nef7 shows a statistically insignificant decrease in CD4 expression.  This 
difference is likely due to the different cell types used, as HeLa cells have been shown to 
have a high recycling rate for CD4.  Therefore, any internalized CD4 is quickly replaced 
at the cell surface, resulting in a smaller overall decrease in surface expression of CD4.   
 
Inhibition of HIV-1 infectivity using Nef7.A3G 
Because Nef7.A3G is incorporated into progeny viruses, we expected that it would retain 
the A3G ability to restrict the infectivity of HIV-1, and this was indeed the case.  In a 
single-cycle HIV infectivity assay Nef7.A3G-containing HIV virions showed a dramatic 
reduction in infectivity (Fig. 18-20).  This reduction was consistent across all cell types 
used and with both VSV-G pseudotyped viruses and viruses expressing X4- and R5-
tropic HIV receptors, confirming that fusion to Nef7 restores the anti-HIV phenotype of 
A3G in the presence of Vif.  In order to determine whether the Nef7.A3G fusion protein 
was Vif-resistant, we expressed Nef7.A3G, Nef7.A3G(D128K), Nef7.A3G(E259Q), and 
A3G in the presence or absence of Vif and analyzed both cellular expression levels and 
virion incorporation (Fig. 17).  Nef7.A3G(D128K) had the highest level of intracellular 
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expression, followed by Nef7.A3G and Nef7.A3G(E259Q).  The A3G protein by itself 
had lower expression than any of the Nef7 fusion proteins, indicating that Nef7.A3G 
fusion proteins are partially Vif-resistant, possibly due to structural constraints on Vif 
binding.  However, the difference between virion incorporation of Nef7.A3G and 
Nef7.A3G(D128K) is not as great as the differences in their cellular expression.  This 
suggests that the slight Vif-resistance of Nef7.A3G is not solely responsible for its 
increased virion incorporation. 
 
We theorized that specific targeting of Nef7.A3G fusion proteins to HIV infected cells 
could inhibit the spread of HIV infection by allowing it to be incorporated into the 
progeny viruses produced from those cells and thus restrict the further spread of HIV 
from all targeted cells.  To test this, we created VLP that were pseudotyped with CD4 and 
CXCR4, allowing their targeting to HIV-infected cells through an “inverse fusion” 
process where the CD4 and CXCR4 on the VLP bind to the gp120 expressed on the 
surface of HIV infected cells.  We infected Jurkat T cells with HIV-1, then treated them 
with pseudotyped VLP containing Nef7.A3G, and monitored virus production over 
multiple rounds of infection (Fig. 22).  In this study we used a ratio of input virus to VLP 
of 1:10.  This ratio is very important, as a higher ratio would result in a higher magnitude 
of antiviral effect.  The results confirm that Nef7.A3G-containing VLP inhibit the spread 
of HIV in infected Jurkat cells.  Furthermore, the specific targeting of infected cells by 
inverse fusion should minimize bystander toxicity, increasing the usefulness of this 
strategy as a therapeutic platform to inactivate HIV-1 and suppress HIV-1 replication.   
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Effect of Nef on HIV-1 virological synapse formation 
We report here that Nef enhances the formation of and transfer of virus through HIV-1 
virological synapses.  In cells infected with WT HIV virus, there was a significant 
increase in the number of synapses formed as compared to cells lacking Nef (Fig. 23).  
To ensure that this increase in the number of VS formed translated to a similar increase in 
the amount of virus transferred to target cells, we took advantage of a previously 
described assay for VS-dependent transfer.  In this system, the contribution of cell-free 
virus to target cell infection has been shown to be negligible, at less than 1% (Sol-Foulon, 
Sourisseau et al. 2007).  In our experiments, WT HIV showed significantly increased 
transfer of virions to target cells as compared to HIVΔNef virus (Fig. 25).  Importantly, 
we included as negative controls known inhibitors of VS transfer: cytochalasin D, which 
inhibits the actin restructuring required for VS formation; and piceatannol, a Syk tyrosine 
kinase inhibitor that has particularly high activity against ZAP70.  Both of these 
inhibitors resulted in VS transfer of virus that was similar to that of HIVΔNef.   
 
HIV-1 spread through virological synapses is faster than viral spread though cell-free 
virus in vivo, but in most tissue culture conditions the infected cell density is too low to 
favor VS-dependent over cell-free transfer.  Additionally, by the time the cell density and 
number of infected cells becomes high enough to result in high VS formation rates, the 
amount of cell-free virus overwhelms any change in replication kinetics that might be 
seen due to inhibition of VS formation.  Therefore, in order to see whether or not Nef’s 
effect on VS formation resulted in differences in viral spread, we monitored replication 
kinetics in a situation that favored VS-dependent virus spread over cell-free virus spread: 
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high cell density; 33% p24+ (infected) cells at the start of the experiment, with the fusion 
inhibitor T-20 also added to one set in order to eliminate any virus spread resulting from 
cell-free virus.  We found that in these VS-favorable conditions there is a small but 
significant lag in the replication kinetics of HIVΔNef infections as compared to WT 
infections (Fig. 26B).  This lag becomes more pronounced and longer-lived when T-20 is 
included to eliminate any cell-free infections (Fig. 26B).  
 
There is some controversy regarding the means of virion entry into target cells during 
HIV-1 VS, with some studies reporting uptake via endocytosis (Chen, Hubner et al. 2007; 
Bosch, Grigorov et al. 2008; Hubner, McNerney et al. 2009) and some reporting a need 
for gp120-CCR5/CXCR4 dependent fusion (Martin, Welsch et al.; Massanella, 
Puigdomenech et al. 2009).  Because we saw significant virus spread in our cultures even 
in the presence of T-20, we conclude that in our system virion entry into target cells 
during VS is at least partially fusion-independent.  This does not, however, eliminate the 
possibility that virion entry is a combination of endocytosis and fusion.  Taken together, 
our data show that Nef enhances the spread of HIV-1 through virological synapses, and 
that this enhancement is relevant to HIV-1 spread in both the short and long term. 
 
Nef-induced polarization of virological synapse components 
Previous studies have indicated that Nef may affect lipid raft dynamics (Simons and 
Ehehalt 2002; Riethmuller, Riehle et al. 2006).  Specifically, Nef increases the size of 
lipid rafts during IS formation and the localization of tyrosine kinases to rafts (Djordjevic 
et al. 2004).  Because of the importance of lipid raft clustering in VS formation we 
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believed that this might be an important mechanism of Nef enhancement of VS 
formation.  To test this, we examined the distribution of GM1 in Nef-expressing cells 
using three different methods: confocal microscopy (Fig. 27A, 32), FACS analysis of 
GM1 intensity (Fig. 29, 34A), and raft floatation assays (Fig. 36).  All three techniques 
show that Nef increases the size of lipid rafts, likely by inducing clustering of small rafts 
to form larger ones. 
 
CD81 is another important component of virological synapses and is responsible for 
preventing the formation of syncytia during cell-cell contacts, thus allowing the infected 
cell to detach and form a VS with another target cell (Weng, Krementsov et al. 2009).  
We analyzed the surface distribution of CD81 in Nef-expressing cells in the same way as 
GM1 and found that Nef expression also polarized surface CD81 (Fig. 28, 33, 34B, 37).  
 
We then wished to determine whether Nef affected ZAP70 distribution during virological 
synapse formation.  We therefore examined ZAP70 staining during VS formation in WT 
HIV and HIVΔNef infections and found that there was a large increase in both ZAP70 
and total pTyr localization to the VS in the presence of Nef (Fig. 38, 39).  Interestingly, 
the localization of p24 to the VS was also increased to a similar degree, suggesting that 
the two were recruited together.  Given the localization of ZAP70 to lipid rafts, the 
preponderance of CD81 in lipid rafts (Jolly and Sattentau 2007), and the assembly of 
HIV-1 virions there, it is likely that the polarization of all these VS components is 
accomplished by the clustering of lipid rafts, which then indirectly bring the other 
components to the synapse.  
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Nef residues involved in clustering of virological synapse components 
To determine the Nef domains responsible for the polarization of virological synapse 
components, we took advantage of a previously constructed panel of Jurkat cells stably 
expressing a series of Nef mutants fused to GFP.  We performed our flow cytometry 
polarization assay on each mutant, using both GM1 and CD81 and found that the 
alteration of both GM1 and CD81 distribution requires myristoylation of Nef as well as a 
functional N-terminal basic region (Fig. 34).  Interestingly, both these determinants are 
involved in the localization of Nef to the plasma membrane (Geyer, Fackler et al. 2001; 
Giese, Woerz et al. 2006), suggesting that membrane localization of Nef is extremely 
important in this process (see Fig. 5).  We also demonstrated that Nef-induced clustering 
of lipid rafts and CD81 is driven by actin reorganization, as treatment with cytochalasin 
D completely abolished all polarization. 
 
The strict requirement for membrane localization, as well as the dependence upon actin 
reorganization, led us to believe that Nef-induced activation of Vav may be responsible 
for the polarization of VS components.  Furthermore, it has been previously shown that 
clustering of lipid rafts in immunological synapse formation was largely dependent upon 
Vav activation (Villalba, Bi et al. 2001).  We therefore created a replication-competent 
HIV-1 construct with a mutation at F191, the residue responsible for the recruitment of 
Vav to its signaling cascade in lipid rafts (Krautkramer, Giese et al. 2004).  As expected, 
HIV.nef-F191A exhibited decreased virological synapse formation (Fig. 43), with a 
corresponding decrease in the amount of VS-dependent Gag transfer (Fig. 44).  To 
determine what, if any, effect mutating F191 had on the polarization of virological 
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synapse components, we performed our flow cytometry-based GM1 polarization assay 
and showed that the Nef-induced polarization of VS components was indeed mediated by 
Vav, as HIV.nef-F191A showed reduced clustering of GM1, on level with that of 
HIVΔNef (Fig. 45).   
 
Nef-induced protrusions as an indication of viral transfer 
In addition to virological synapses, there exists a second means of direct cell-cell spread 
of HIV-1.  These are more long-range and are known as nanotubes or filopodial bridges 
(Sherer, Lehmann et al. 2007; Davis and Sowinski 2008; Sowinski, Jolly et al. 2008).  It 
has been hypothesized that these protrusions are remnants of virological synapses, left 
after cell separation, or that they are the initial step in VS formation, establishing cell-cell 
connections that allow the infected and uninfected pair to come together more efficiently 
(Haller and Fackler 2008).  Intriguingly, it has recently been reported by multiple groups 
that Nef induces protrusions in expressing cells (Nobile, Rudnicka et al. 2010; Xu, 
Santini et al. 2009); these have been shown to transfer Nef to bystander cells (Xu, Santini 
et al. 2009).  It is likely that these filopodia are analogous to the nanotubules that form 
between infected and uninfected cells.  We examined F-actin in Nef-expressing cell lines 
and confirmed this phenomenon (Fig. 40A).  Additionally, we showed that the formation 
of Nef protrusions requires a functional SH3-binding domain in Nef.  Because of the 
possibility of these protrusions being analogous to VS transfer, we treated cells with 
piceatannol to examine the involvement of ZAP70 in this process.  We found that 
treatment with piceatannol completely abolished the protrusions, which provided 
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additional support for the theory that Nef protrusions are associated with VS viral transfer 
(Fig. 40B).   
 
ZAP70 involvement in Nef enhancement of HIV-1 virological synapses 
In an effort to further elucidate the mechanism of Nef enhancement of virological 
synapse formation, we generated a series of replication-competent Nef-mutant viruses 
(Fig. 42).  Our first mutant, mentioned previously, was HIV.nef-F191A, which is 
defective in Nef-mediated recruitment of Vav to lipid raft microdomains.  Our second 
mutant generated was HIV.nef-AxxA, which we used to confirm the importance of Nef 
activation of ZAP70 by its SH3 domain.  Thirdly, we wished to confirm the idea that 
ZAP70 was not specifically recruited to the VS, but instead was recruited indirectly.  To 
this end, we generated the HIV.nef-62AAAA65 mutation, which abolishes Nef-mediated 
recruitment of ZAP70 to its signaling complex (Atkins, Thomas et al. 2008).  We 
examined these HIV-1 mutants for VS formation as well as VS-dependent viral transfer 
(Fig. 43, 44).  We found that, as expected, HIV.nef-AxxA was similar to HIVΔNef in both 
cases.  We also confirmed the indirect mechanism of ZAP70 localization to the 
virological synapse, as HIV.nef-62AAAA65 behaves like WT HIV during VS assays.   
 
Analysis of pZAP70 levels in infected Jurkat cells showed that while HIV.nef-F191A had 
little effect on ZAP70 phosphorylation as compared to WT HIV, infection with both the 
HIV.nef-AxxA and HIV.nef-62AAAA65 viruses resulted in decreased pZAP70 (Fig. 46).  
Since HIV.nef-62AAA65 is known to have decreased ZAP70 activation in at least one 
pathway, that of MHC I downregulation, it is not unexpected that the whole cell pZAP70 
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levels would be affected.  However, based on the data from our VS assays, we conclude 
that this decrease may be localized to a different subcellular location than the ZAP70 
needed for VS transfer, as HIV.nef-62AAA65 had no effect on virological synapses.  This 
is reasonable since the acidic domain of Nef responsible for the recruitment of ZAP70 in 
the MHC I downregulation cascade acts through its binding to PACS-2, which largely 
locates to the ER and mitochondria (Simmen, Aslan et al. 2005; Atkins, Thomas et al. 
2008).  Conversely, since HIV.nef-AxxA showed both decreased pZAP70 and lower VS 
transfer, we propose that the pool of ZAP70 that is localized in lipid rafts and is 
necessary for virological synapses requires the PxxP domain of Nef to function fully. 
 
Virological synapse formation in primary CD4+ T lymphocytes 
Finally, we confirmed the effect of Nef on VS formation in primary cells.  Interestingly, 
we found that Nef has a greater effect on VS formation in primary cells as compared to 
Jurkat cells, as during Gag transfer analysis in Jurkat cells HIVΔNef results in 
approximately 63% of WT transfer, whereas in primary cells this decreased to 
approximately 50% of WT (Fig. 47).  Additionally, we found that the total Gag transfer 
to target cells is increased in primary cells as compared to Jurkat cells.  This supports an 
idea mentioned before that primary cells may favor VS-dependent viral spread over cell-
free spread, while the opposite is true for cell lines (Puigdomenech, Massanella et al. 
2009).  This theory may also explain why VS-dependent viral spread is more relevant in 
many in vivo situations than cell-free viral spread.  Our data reveals an interesting 
mechanism of Nef-mediated enhancement of HIV-1 virological synapses, wherein Nef 
exhibits a two-pronged approach to amplify both formation of, and transfer of virus 
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through, HIV-1 virological synapses (Fig. 48).  This effect may partially explain the 
greater infectivity of WT HIV-1 over Nef-deleted HIV-1 in primary cells.
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Figure 48. Proposed working model for Nef-mediated enhancement of HIV 
virological synapses.  Nef induces polarization of VS components through an actin-
dependent process that requires its N-terminal basic region.  This process is driven by 
Nef recruitment of Vav.  Additionally, Nef induces protrusions that require activation of 
ZAP70 to form, and likely are an indication of VS-dependent viral transfer.  When both 
Nef functions are working properly, there is optimal formation of virological synapses 
and spread of HIV virus through them. 
 
  
 191 
PERSPECTIVES 
 
HAART has reduced the AIDS-associated mortality in developed countries by up to 80-
90%, although the effect is much lower in developing countries where anti-retroviral 
drugs are cost-prohibitive and rare (Hammer, Eron et al. 2008; Ho and Bieniasz 2008).  
Proper application of HAART therapy can reduce plasma viral loads to undetectable 
levels, but it cannot eradicate the virus.  Furthermore, replication can sometimes continue 
undetected in lymphoid tissues, and if treatment is stopped for any reason viral loads 
become very high.  Unfortunately, the high cost of HAART and non-compliance issues 
due to toxicity often contribute to the rise of HAART-resistant HIV-1 strains.  This has 
made the development of alternative anti-HIV therapies a priority.  Because of the 
shortcomings of current anti-HIV therapies, there has recently been increased interest in 
exploiting cellular proteins involved in the HIV-1 lifecycle in order to develop new 
therapies.  Importantly, due to the recent revelation of the importance of virological 
synapses in the spread of HIV-1 any future therapies would need to take into account the 
differing requirements for cell-dependent and cell-free virus spread in order to be 
completely effective in vivo.  At the current time, however, little is known about the 
cellular determinants of HIV-1 virological synapse regulation, and even less is known 
about the viral determinants of VS regulation.  Therefore, the regulatory mechanisms of 
HIV-1 virological synapses need to be elucidated in order to develop the most effective 
anti-HIV therapies. 
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Nef7 as a platform for therapeutic protein delivery 
What we have shown here is a proof-of-concept that Nef7 works well as a carrier 
platform for delivery of therapeutic molecules.  This strategy has many potential uses 
aside from the Nef7.A3G fusion protein.  Because of its high virion incorporation, Nef7 
fusion proteins can be used to target several components of the HIV-1 virion, such as 
Nef7.EDN targeting of the HIV-1 tRNA primer.  Moreover, Nef fusion proteins can be 
adapted to deliver anti-HIV therapeutic proteins or components directly into HIV-1 or 
HIV-infected cells.  This is a great advantage over traditional means of antiviral therapy, 
as this direct targeting of infected cells greatly diminishes bystander cell toxicity, and 
thus could result in fewer potential side effects during treatment.  In a clinical setting 
VLP, such as those used in gene therapy, could be used to deliver Nef7.A3G to target 
cells.  This strategy would require continual treatment, but since the treatment involved 
delivery of protein there would be no concerns about Nef7 reverting to WT Nef.   
 
An alternative strategy would be to deliver Nef7.A3G DNA that is driven by the HIV-1 
LTR and allowed to integrate into the host cell chromosome.  If that cell is later infected 
by HIV-1 transcription of the Nef7.A3G gene would commence, and result in inhibition 
of viral spread.  This strategy is more like a preventative treatment.  It would be more 
proactive and stop the infection immediately; however, since the treatment involves 
delivery of Nef7 DNA there is the chance of revertants to WT Nef given the selective 
pressures to produce WT Nef in vivo.  Since Nef7 is derived from F12-HIVnef, a mutated 
Nef gene that did manage to persist in vivo, it is possible that Nef7 would also manage to 
persist without reverting back to a WT Nef phenotype but this would have to be tested. 
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Another potential use of Nef7, aside from delivery of therapeutic proteins to viral 
particles, is as a protein carrier for lipid raft localization.  Since Nef7 owes its enhanced 
virion incorporation largely to its increased localization to lipid rafts as compared to WT 
Nef, Nef7 could work equally well for delivering proteins to lipid rafts as for delivering 
proteins to HIV-1 virions.  This could potentially be a very useful tool, as lipid rafts tend 
to have very large concentrations of signaling molecules.  Indeed, many important 
signaling processes require the integrity of lipid rafts or the aggregation of lipid rafts into 
large signaling platforms.  As such, any disorder that involves aberrant signaling from 
signal cascades dependent upon lipid rafts could potentially be affected by Nef7 fusion 
proteins. 
 
Further characterization of the molecular mechanism responsible for Nef7’s higher virion 
incorporation and the structure-function relationship of Nef7 shall surely help fine tune 
this strategy to minimize any residual pathogenic activity of Nef7 and to maximize the 
benefits of this novel strategic anti-HIV platform for its potential clinical translation. 
 
Potential of Nef7 as a laboratory research tool 
Nef7 fusion proteins could also be used for novel experimental procedures in the 
laboratory.  For example, a Nef7.GFP fusion protein could be used to track viral cores at 
early stages of infection, and a Nef7.luciferase fusion protein could be used as a sensitive 
assay for measuring virus production.  The high virion incorporation of Nef7 would allow 
it to be utilized for any procedure that requires quantification or identification of viral 
particles.  This would not even necessarily need to be HIV-1 virions, as MLV virions also 
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exhibit high virion incorporation of Nef7.  It would be interesting to determine whether 
Nef7 could be used as a general tool for viral tracking, or whether it only works with 
enveloped viruses, or only with retroviruses. 
 
Nef involvement in immunological and virological synapses 
Given that Nef has been shown to inhibit the formation of immunological synapses, at 
first glance it seems contradictory that Nef also promotes the formation of virological 
synapses.  However, further examination of the mechanisms of Nef down-modulation of 
the immunological synapse reveals that Nef mainly accomplishes this by altering the sub-
cellular localization of CD3 and Lck.  In the context of the virological synapse this would 
not be relevant, as CD3 does not localize to the HIV-1 virological synapse.  It has not 
been determined what, if any, involvement Lck has in virological synapses, but as the 
majority of Lck is associated with CD4, it is unlikely that Lck would have any great role 
in the effector cell, as CD4 is mostly downregulated from the surface in these cells and so 
does not localize to the virological synapse on that side.  Lck may very well be required 
in the target cell as CD4 is a key component of the target cell virological synapse.   
 
From our data and previous work published by others, it appears as though Nef is 
responsible for a delicate balancing act in infected cells, wherein immunological synapses 
are destabilized at the same time that IS downstream signaling is enhanced, and 
virological synapse formation is promoted.  The two processes may even amplify each 
other.  Since virological synapses share at least some components with immunological 
synapses, the destabilization of immunological synapses may free up components for 
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virological synapses that may otherwise be scarce.  This may be even more important in 
the context of an infected individual, because lymphoid organs are such important sites of 
viral replication in vivo.  These sites have extremely high cell density, which would be a 
great asset for virological synapse formation, but they are also the main site of antigen 
presentation to CD4+ T lymphocytes by antigen presenting cells.  This would result in a 
preference for immunological synapse formation over that of virological synapse 
formation, unless there was something to discourage their formation.  It would be very 
interesting to determine the rates of VS formation with and without concurrent IS 
stimulation.  It may be that Nef has an even greater impact on virological synapse 
formation in vivo than has been shown here because of its ability to destabilize the 
immunological synapse.  Therefore, this new function of Nef may partially explain its 
impact on HIV-1 replication and pathogenesis in infected individuals. 
 
Virological synapses may also play an important role in horizontal and vertical 
transmission of HIV-1.  Infected cells can exist in the bodily fluids that transmit HIV-1, 
particularly contaminated blood but others as well.  These infected cells could then 
transfer HIV-1 to susceptible cells in the newly exposed individual much more efficiently 
that cell-free virus in those same fluids.  Additionally, infected cells are much less fragile 
than cell-free virus, which does not persist outside of the body in an infectious form for 
more than a few minutes.  Therefore, infected cells may provide not only a more efficient 
means of transmitting HIV-1, but also a more stable one. 
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Nef transfer to target cells 
During HIV-1 infection, only a relatively small percentage of cells are infected at any 
given time.  However, there are widespread effects on the immune system, even in 
uninfected cells.  Our lab and others have shown that Nef can be transferred to uninfected 
target cells through nanotube protrusions, and this may be at least a partial cause of the 
immune dysregulation seen.  This is supported by the findings that Nef induces apoptosis 
in bystander cells and can inhibit antibody class switching to IgG/IgA in bystander B 
cells. 
 
It is possible that Nef may also play a role in establishing a virological synapse on the 
part of the target cell.  The nanotubes that seem to play a role in virological synapse-
dependent viral transfer also have been shown to transfer Nef to bystander cells.  As 
mentioned previously, there is a theory that these protrusions are remnants of virological 
synapses, left after cell separation, or that they are the initial step in VS formation, 
establishing cell-cell connections that allow the infected and uninfected pair to come 
together more efficiently.  Given that conduits can form without stimulation from a 
virological synapse, or even without infection, it seems likely that Nef-induced 
protrusions are involved at the earlier stage of virological synapses.  If this is indeed the 
case, it is possible that Nef could be transferred to the target cells of a virological synapse 
prior to its establishment per se, and “prime” it for engagement with the effector cell.  An 
interesting next step could be to determine whether Nef is transferred to the target cells of 
a virological synapse, and if so, what affect this may have on the target cell’s ability to 
engage in the synapse.   
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Signaling pathways at the virological synapse 
Even with these new insights into the required components of the virological synapse, 
there is still very little known about the signaling pathways involved in the effector cell 
and even less known about those involved in the target cells.  Adhesion molecules have 
also been shown to play a role in downstream signaling at the virological synapse, as 
antibodies directed against ICAM-1 signaling, which still allow conjugate formation, 
result in impaired virological synapse formation.  Therefore, there is an unknown 
pathway signaling through the adhesion molecules of a VS.   
 
The other signaling pathway known to be involved in virological synapses includes 
ZAP70.  Prior to this work, ZAP70 was known to increase the transfer of virions to target 
cells, but did not affect conjugate formation.  The authors of this study proposed that 
ZAP70 increased the localization of Gag to the synapse, as they found more intense 
points of Gag staining in the presence of ZAP70 than without (Sol-Foulon, Sourisseau et 
al. 2007).  However, close analysis of the VS confocal images shows Gag at the tips of 
protruding portions of the infected cell.  Therefore, this more intense staining of Gag in 
the presence of ZAP70 may not be an overall increase of Gag to the VS, but instead an 
indication of ZAP70 increasing the transfer of Gag through protrusions into target cells.  
It is still unknown how ZAP70 activation causes the formation of actin protrusions, so it 
would be beneficial to examine this pathway in more detail in order to further elucidate 
the mechanisms of virological synapse formation. 
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Nef enhancement of infectivity in primary cells 
The most elusive Nef property investigated to date is its ability to increase the infectivity 
of HIV-1 in primary cells.  This difference in infectivity was most evident in infections of 
unstimulated PBMC at low MOI.  The finding that Nef-containing virions exhibited 
greater infectivity in single round infectivity assays partially explains this phenomenon.  
Unfortunately, it also led to a focus on the effect of Nef in cell-free virus, and since that 
time almost all efforts to elucidate the mechanism behind Nef-mediated enhancement of 
replication in primary calls has involved the mechanism behind the increased infectivity 
of cell-free virus.  However, even taking into account the equivalent infectivity between 
the Nef+ and Nef- viruses, comparison of PBMC infections in early studies still reveals 
delayed viral replication in the absence of Nef, suggesting that there is a secondary 
mechanism involved in the Nef-mediated enhancement of infectivity in primary cells that 
involves secondary viral spread (Miller, Warmerdam et al. 1994). 
 
Our findings that Nef enhances the spread of HIV-1 through virological synapses may 
offer an explanation for this observed difference in replication, even with adjusting for 
the increased infectivity of cell-free virions.  If, as we and others have proposed, primary 
cells preferentially utilize virological synapses over cell-free virus, this may be a more 
relevant explanation for the increased infectivity of Nef+ viruses in primary cells than an 
increase in free-virus infectivity.  It would be interesting to attempt to separate the 
relative contributions of cell-free and cell-cell viral infection when determining 
differential replication kinetics in primary cells in order to resolve this question.  This 
could potentially be addressed by using a transwell culture, wherein infected cells are 
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separated from target cells by a membrane that allows cell-free virus to pass though but 
not infected cells.  The replication kinetics of the cell-free HIV-1 could then be 
determined, and then differences between the replication kinetics of mixed infected and 
uninfected cultures and the cell-free virus culture would demonstrate the contribution of 
VS-mediated virus spread. 
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